Session Title: ASCO/European CanCer Organisation (ECCO) Joint Session: Quality Improvement through Outcome Registration in Gastrointestinal Cancer

Session Type: Special Session

Time: 8:00 AM - 9:15 AM

Location: E353

- Quality Improvement through Outcome Registration in Gastrointestinal Cancer
  *Cornelis J. H. Van De Velde, MD, PhD (Co-Chair)*
- American College of Surgeons’ NSQIP Oncology
  *Karl Y. Bilimoria, MD, MS*
- Consortium for Optimizing Surgical Treatment of Rectal Cancer (OSTRiCh)
  *David Dietz, MD*
- Closing Remarks
  *Michael Paul Link, MD (Co-Chair)*

Session Title: Early Drug Development: Casting a Wide Net versus Preselecting a Narrow Audience

Session Type: Education Session

Time: 8:00 AM - 9:15 AM

Location: E354b

- Molecular Genetic Selection for Patients in Phase I: Looking for Outliers, Fearful of Invisible Gorillas
  *Anthony W. Tolcher, MD (Chair)*
- Biomarker-Driven Patient Selection from Start to Finish
  *Josep Tabernero, MD*
- When Can Phase II Data Be Sufficient for Adopting a New Standard Therapy?
  *Bruce Allan Chabner, MD*

Session Title: The Management of Less Common but Complex Upper Gastrointestinal Malignancies: Hepatocellular Carcinoma, Pancreatic Neuroendocrine Tumors, and Biliary Tract Tumors

Session Type: Education Session

Time: 8:00 AM - 9:15 AM

Location: N Hall B1

- The Current Therapeutic Approach for Pancreatic Neuroendocrine Tumors: Current Status and Future Directions
  *Pamela L. Kunz, MD (Chair)*
  *Andrew X. Zhu, MD, PhD*
- Treatment of Biliary Tract and Gallbladder Cancers
  *Jordan Berlin, MD*

Session Title: What the Busy Oncologist Needs to Know about Gastrointestinal Stromal Tumor

Session Type: Education Session

Time: 8:00 AM - 9:15 AM

Location: S406

  *Jaap Verweij, MD, PhD (Chair)*
- Mutational Testing in Gastrointestinal Stromal Tumor: When to Do It and How Does It Help?
  *William D. Tap, MD*
• What Does One Do When Standard Tyrosine Kinase Inhibitor Therapy Fails in Gastrointestinal Stromal Tumor?
  
  Michael C. Heinrich, MD

**Session Title:** Optimal Use of Hypomethylating Agents and New Strategies - Ticketed Session

**Session Type:** Meet the Professor Session

**Time:** 8:00 AM - 9:15 AM

**Location:** E451a

• Optimal Use of Hypomethylating Agents and New Strategies
  
  Alan F. List, MD

**Session Title:** Integrating Testing for Hereditary Cancer Syndromes in the Oncology Practice - Ticketed Session

**Session Type:** Clinical Problems in Oncology Session

**Time:** 8:00 AM - 9:15 AM

**Location:** E451b

• Overview: Selecting the Right Patient and Ordering the Right Test
  
  James M. Ford, MD (Chair)

• Effective Counseling of the Patient Before and After Testing for a Hereditary Cancer Syndrome
  
  Wendy Kohlmann, MS

• Impact of Cancer Genetic Testing on Patients and Families
  
  Kathleen Blazer, MS

**Session Title:** Highlights of the Day II Session

**Session Type:** Highlights of the Day

**Time:** 8:00 AM - 9:30 AM

**Location:** E Hall D1

• Chair
  
  Kathy Miller, MD

• Breast Cancer - HER2/ER
  
  Anne F. Schott, MD

• Myeloma
  
  Rafat Abonour, MD

• Head and Neck Cancer
  
  Christine H. Chung, MD

• Central Nervous System Tumors
  
  Joon H. Uhm, MD

• Gastrointestinal (Colorectal) Cancer
  
  George A. Fisher, MD, PhD

**Session Title:** Cancer Prevention/Epidemiology

**Session Type:** Oral Abstract Session

**Time:** 8:00 AM - 11:00 AM

**Location:** S100a

• Co-Chair
  
  Susan M. Domchek, MD

• Co-Chair
  
  Abenaa M. Brewster, MD, MHS

• A phase III prevention trial of low-dose tamoxifen in HRT users: The HOT trial. (Abstract #1500)
  
  Bernardo Bonanni

• Estrogen plus progestin (E+P) and breast cancer incidence and mortality. (Abstract #1501)
  
  Rowan T. Chlebowski
Brd. 17
• BMI and long-term changes in BMI and risk of cancer mortality in a large cohort study. (Abstract #1502)
  Niloofar Taghizadeh
• Discussion
  Kathleen I. Pritchard, MD
• Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study. (Abstract #1503)
  Ronac Mamtani
• Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients. (Abstract #1504)
  Dana Marie Walker
• Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the ASCO Quality Oncology Practice Initiative (QOPI). (Abstract #CRA1505)
  Marie Wood
• Sensitivity of clinical BRCA1 testing compared with linkage analysis. (Abstract #1506)
  Payal D. Shah
• The APC I1307K polymorphism as a significant risk factor for CRC in average-risk Ashkenazi Jews. (Abstract #1507)
  Ben Boursi
• Use of PTEN protein dosage to predict for underlying germ-line PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes. (Abstract #1508)
  Joanne Y. Y. Ngeow
• Discussion
  Stephen B. Gruber, MD, PhD, MPH

Leukemia, Myelodysplasia, and Transplantation
Session Title: Leukemia, Myelodysplasia, and Transplantation
Session Type: Oral Abstract Session
  Time: 8:00 AM - 11:00 AM
  Location: E354a
• Co-Chair
  Attaya Suvannasankha, MD
• Co-Chair
  Jae Hong Park, MD
• Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. (Abstract #6500^)
  Max Topp
• Inotuzumab ozogamicin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). (Abstract #6501)
  Elias Jabbour
• A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients. (Abstract #6502)
  Sucha Nand
• Discussion
  Bruno C. Medeiros, MD
• PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. (Abstract #6503)
  Jorge E. Cortes
Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. (Abstract #6504)

Andreas Hochhaus

Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENEStcmr 12-month (mo) follow-up. (Abstract #6505^)

Jeffrey Howard Lipton

Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. (Abstract #6506)

Neil P. Shah

Discussion

Michael J. Mauro, MD

The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (Abstract #6507)

John C. Byrd

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. (Abstract #6508)

Samantha Mary Jaglowski

Discussion

Constantine Si Lun Tam, MBBS

Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Session Type: Oral Abstract Session

Time: 8:00 AM - 11:00 AM

Location: E Hall D2

Co-Chair

Heather A. Wakelee, MD

Co-Chair

Nathan A. Pennell, MD, PhD

Brd. 7

Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature. (Abstract #7000)

Satomi Yamamoto

GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study. (Abstract #7001)

Rudolf M. Huber

Brd. 8

Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC). (Abstract #7002)

Hak Choy

Discussion

Wilfried Ernst Erich Eberhardt, MD

A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509. (Abstract #7003)

Yoshikazu Kotani
Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer. (Abstract #7004)

Keunchil Park

SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC). (Abstract #7005)

Jeffrey Warren Allen

Discussion

David R. Gandara, MD

Comprehensive genomic characterization of squamous cell carcinoma of the lung. (Abstract #7006)

Ramaswamy Govindan

Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. (Abstract #7007)

Frances A. Shepherd

Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial. (Abstract #7008)

Eric L. Grogan

Discussion

Tetsuya Mitsudomi, MD, PhD

---

Session Title: Melanoma/Skin Cancers  
Session Type: Oral Abstract Session  
Time: 8:00 AM - 11:00 AM  
Location: E Arie Crown Theater

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. (Abstract #LBA8500^)

Axel Hauschild

BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). (Abstract #8501)

John M. Kirkwood

Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. (Abstract #8502^)

Paul B. Chapman

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600Emelanoma. (Abstract #8503^)

Jeffrey Alan Sosman

Discussion

Michael B. Atkins, MD

Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (Abstract #8504)

Lawrence E. Flaherty
Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408). (Abstract #8505)

Peter Mohr

Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma. (Abstract #8506)

Bin Lian

Discussion
Lynn Mara Schuchter, MD

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (Abstract #8507)

F. Stephen Hodi

Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. (Abstract #8508)

Omid Hamid

Discussion
Antoni Ribas, MD

Session Title: Patient and Survivor Care
Session Type: Oral Abstract Session
Time: 8:00 AM - 11:00 AM
Location: S404

Chair
Steven M. Grunberg, MD

Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial. (Abstract #9000)

Qamar J. Khan

Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2. (Abstract #9001)

Debra L. Barton

Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial. (Abstract #9002)

Sriram Yennurajalingam

Discussion
Karen Michelle Mustian, PhD, MPH

Cluster-randomized trial of early palliative care for patients with metastatic cancer. (Abstract #9003)

Camilla Zimmermann

A video decision support tool for CPR in advanced cancer: A randomized controlled trial. (Abstract #9004)

Angelo E. Volandes

ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. (Abstract #9005)

Dino Amadori

Discussion
Thomas J. Smith, MD

Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and myocardial dysfunction. (Abstract #9006)

Giovanni Mantovani
• Post diagnosis weight gain and the role of exercise in breast cancer survivors. (Abstract #9007)
  Tara Beth Sanft
• Electronic self-report assessment for cancer: Results of a multisite randomized trial. (Abstract #9008)
  Donna Lynn Berry
• Discussion
  Roisin M. Connolly, MD

**Session Title:** Pediatric Oncology II  
**Session Type:** Oral Abstract Session  
**Time:** 8:00 AM - 11:00 AM  
**Location:** S504

• Co-Chair  
  Patrick Leavey, MD
• Co-Chair  
  Katherine A. Janeway, MD

• Vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children’s Oncology Group (COG). (Abstract #9509)
  David Walterhouse
• Discussion
  Leo Mascarenhas, MBBS, MD, MS

• Development of prognostic molecular markers in pediatric rhabdomyosarcoma based on gene expression and copy number variations. (Abstract #9510)
  Edoardo Missiaglia
• Identification of TNK2 as a critical kinase in rhabdomyosarcoma through a loss of function shRNA screen. (Abstract #9511)
  Fernanda Irene Arnaldez

• Evaluation of the effect of care at NCI comprehensive cancer centers (NCICCCs) on disparities in outcome within adolescents and young adults (AYAs) with cancer. (Abstract #9512)
  Julie Anna Wolfson

• New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study. (Abstract #CRA9513)
  Chaya S. Moskowitz
• Discussion
  Maureen Megan O’Brien, MD

• Increasing risk of chronic health conditions in aging survivors of childhood cancer: A report from the childhood cancer survivor study. (Abstract #9514)
  Gregory T. Armstrong

• A large prospective trial of children with unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: A Children’s Oncology Group (COG) study. (Abstract #9515)
  Murali M. Chintagumpala

• Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma. (Abstract #9516)
  Navin R. Pinto
• Discussion
  Jun J. Yang, PhD
• Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma and other pediatric solid malignancies: A European ITCC study. (Abstract #9517)

  Angela Di Giannatale

  **Session Title:** Tumor Biology
  **Session Type:** Oral Abstract Session
  **Time:** 8:00 AM - 11:00 AM
  **Location:** S100bc

• Co-Chair
  Robert Arthur Kratzke, MD

• Co-Chair
  Priyanka Sharma, MD

• Gene expression-based predictors of chemotherapy response in basal-like breast cancer. (Abstract #10500)

  Aleix Prat

• Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. (Abstract #10501)

  Christian F. Singer

• A heuristic platform for clinical interpretation of cancer genome sequencing data. (Abstract #10502)

  Eliezer Mendel Van Allen

• Discussion
  Douglas Yee, MD

• Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). (Abstract #10503)

  Nicholas J. Vogelzang

• Gene expression profiles of circulating tumor cells in metastatic breast cancer patients. (Abstract #10504)

  Bianca Mostert

• Circulating DNA analysis and concordance with tumor section analysis in the detection of KRAS and BRAF point mutations from metastatic colorectal cancer. (Abstract #10505)

  Alain R. Thierry

• Discussion
  Daniel A. Haber, MD, PhD

• DEAR1, a novel tumor suppressor, negative regulator of epithelial-mesenchymal transition, and prognostic factor in non-small cell lung cancer. (Abstract #10506)

  Alfonso Quintas-Cardama

• Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data. (Abstract #10507)

  Michele Beau-Faller

• Discussion
  Pasi A. Janne, MD, PhD

  **Session Title:** Genitourinary (Prostate) Cancer
  **Session Type:** Poster Discussion Session
  **Display Time:** 8:00 AM - 12:00 PM
  **Display Location:** E450a
  **Discussion Time:** 11:30 AM - 12:30 PM
**Discussion Location:** E Arie Crown Theater

- Co-Chair
  
  *Terence W. Friedlander, MD*

- Co-Chair
  
  *Silke Gillessen, MD*

**Brd. 1**
- SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel (DOC) with or without atrasentan (ATR). (Abstract #4547)
  
  *Primo Lara*

**Brd. 2**
- A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4548)
  
  *Dana E. Rathkopf*

**Brd. 3**
- Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. (Abstract #4549)
  
  *Daniel J. George*

**Brd. 4**
- Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. (Abstract #4550)
  
  *Andrew J. Armstrong*

**Brd. 5**
- Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). (Abstract #4551)
  
  *A. Oliver Sartor*

**Brd. 6**
- Development of a nomogram model using a very large sample of patients (pts) to predict the risk of 99mTc-bone scan (BS) positivity in pts receiving androgen deprivation therapy (ADT) for prostate cancer (PCa). (Abstract #4552)
  
  *Geoffrey Gotto*

- Discussion
  
  *Evan Y. Yu, MD*

**Brd. 7**
- Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). (Abstract #4553)
  
  *Diletta Bianchini*

**Brd. 8**
- Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. (Abstract #4554)
  
  *Ecaterina Ileana*

**Brd. 9**
- Association of metabolic syndrome with poorer prostate cancer and overall survival in men receiving androgen deprivation therapy (ADT) for biochemical relapse. (Abstract #4555)
  
  *Sarah Maria Rudman*
Br. 10

- Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. (Abstract #4556)
  
  Eleni Efstatthiou

Br. 11

- Time to testosterone (T) and PSA rises during first “off treatment” interval (1OFF-2ON) of intermittent androgen deprivation (IAD) as prognostic for time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (Abstract #4557)
  
  Evan Y. Yu

Br. 12

- Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4558)
  
  Oscar B. Goodman

- Discussion
  
  Nima Sharifi, MD

Br. 13

- The effect of PSA frequency and duration on PSA doubling time (PSADT) calculations in men with biochemically recurrent prostate cancer (BRPC) after definitive local therapy. (Abstract #4559)
  
  Channing Judith Paller

Br. 14

- Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. (Abstract #4560)
  
  Eric A. Klein

Br. 15

- Gene expression biomarkers to predict overall survival of prostate cancer patients. (Abstract #4561)
  
  Chunde Li

Br. 16

- Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis. (Abstract #4562)
  
  Daniel Costin Danila

Br. 17

- Generation of a prognostic cancer stem-like gene expression signature in men undergoing radical prostatectomy for localized prostate cancer. (Abstract #4563)
  
  Adrian Stuart Fairey

Br. 18

- Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model. (Abstract #4564)
  
  Avishay Sella

Br. 19

- Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer. (Abstract #4565)
  
  Christine Buerki

- Discussion
  
  Lorelei Mucci, MPH, ScD
• Investigator sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. (Abstract #4566)
  
  Richard J. Lee

• Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC). (Abstract #4568)
  
  Michael J. Morris

• Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4569)
  
  Bamidele Adesunloye

• A multinational phase III adjuvant study of immediate (I) versus deferred (D) chemotherapy (C)/hormone therapy (HT) after radical prostatectomy (RP): TAX-3501. (Abstract #4570)
  
  Mario A. Eisenberger

• Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III. (Abstract #4571)
  
  Carol Moinpour

• Discussion
  
  Ulka N. Vaishampayan, MD

---

**Session Title:** Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Session Type:** General Poster Session

**Time:** 8:00 AM - 12:00 PM

**Location:** S Hall A2

---

Brd. 1A

• A mismatch between methods and objectives in phase I drug development: Statistical limitations and personalized medicine—A California Cancer Consortium (CCC) study. (Abstract #2538)
  
  Paul Henry Frankel

Brd. 1B

• Phase Ib study of plitidepsin (APL) with gemcitabine (GEM) in refractory solid tumors and lymphoma patients. (Abstract #2539)
  
  Mark N. Stein

Brd. 1C

• Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level. (Abstract #2540)
  
  Anne Ploquin

Brd. 1D

• Relationship of variability in tumor measurement and response assessment. (Abstract #2541)
  
  Binsheng Zhao

Brd. 1E

• A multicenter phase II neoadjuvant trial of bevacizumab combined with docetaxel plus carboplatin in the treatment of triple-negative breast cancer: Korean Cancer Study Group (KCSG-BR 0905, NCT 01208480). (Abstract #2542)
  
  Hye Ryun Kim
• Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design. (Abstract #2543)

William Leonard Mietlowski

• How to run survival-endpoint phase II trials with 25% to 40% fewer patients. (Abstract #2544)

Michael J. Schell

• Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. (Abstract #2545)

Jung-min Lee

• Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells. (Abstract #2546)

Christopher L. Moertel

• Predictive model for survival and toxicity in early-phase trials in hematology. (Abstract #2547)

Rahima Jamal

• Difference between duration of treatment (DOT) and progression-free survival (PFS) as a marker of unbalanced censoring. (Abstract #2548)

Laleh Amiri-Kordestani

• Recommendation of dose banding of cytotoxics according to pharmacokinetic criteria. (Abstract #2549)

Etienne Chatelut

• Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors. (Abstract #2550)

Serena Marchetti

• Thymidylate synthase genotype specific dosing of capecitabine: Proof of concept phase I study. (Abstract #2551)

Ross A. Soo

• A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer. (Abstract #2552)

Muhammad Yaser Nasim

• Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous dimethane sulfonate (DMS612, NSC 281612) in advanced malignancies. (Abstract #2553)

Susan Elaine Bates

• Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors. (Abstract #2554)

Sandrine J. Faivre
Br. 3D
- Phase I development of a weekly dosing schedule for the oral taxane tesetaxel. (Abstract #2555)
  
  Amy Lang

Br. 3E
- Effect of dexrazoxane on doxorubicin-induced testicular toxicity. (Abstract #2556)
  
  Irit Ben-Aharon

Br. 3F
  
  Romain Coriat

Br. 3G
- Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxic T lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca). (Abstract #2558)
  
  Carlos Almeida Ramos

Br. 3H
- Phase II trial of a GM-CSF-producing and CD40L-expressing cell line combined with allogeneic tumor antigen as a novel vaccine for metastatic lung adenocarcinoma. (Abstract #2559)
  
  Ben C. Creelan

Br. 4A
- Where to look for sentinel node in breast cancer? (Abstract #2560)
  
  Anton J. Scharl

Br. 4B
- A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC). (Abstract #2561)
  
  Daniel M. Geynisman

Br. 4C
- Lymphoid and myeloid biomarkers for clinical outcome of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-tranduced allogeneic prostate cancer cells (GVAX) and ipilimumab in castration-resistant prostate cancer patients. (Abstract #2562)
  
  Alfons JM van den Eertwegh

Br. 4D
- Evaluation of immune activation following neoadjuvant sipuleucel-T in subjects with localized prostate cancer. (Abstract #2563)
  
  Nadeem A. Sheikh

Br. 4E
- Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment. (Abstract #2564)
  
  Lawrence Fong

Br. 4F
- IFN-γ to improve immunotherapy for melanoma. (Abstract #2565)
  
  Marco Donia

Br. 4G
- A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. (Abstract #2566)
  
  Patricia LoRusso
• Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. (Abstract #2567)
  Manuel Hidalgo

Brd. 5A
• A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts. (Abstract #2568)
  Andres Cervantes-Ruiperez

Brd. 5B
• Patient-specific immunotherapy utilizing putative tumor stem cells in patients with metastatic melanoma: A pooled analysis comparing tumor cell and dendritic cell vaccines in two phase II trials and a randomized phase II trial. (Abstract #2569)
  Robert Owen Dillman

Brd. 5C
• Effect of matrix metalloproteinase-2 on antitumor immunity. (Abstract #2570)
  Emmanuelle Godefroy

Brd. 5D
• Correlation of interferon-g (IFN-γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC). (Abstract #2571)
  John Charles Morris

Brd. 5E
• Does the addition of molecular targeted therapy to standard treatments lead to better or worse outcomes overall? A systematic review of EGFR-targeted therapies used in combination with standard treatments. (Abstract #2572)
  Jennifer Rauw

Brd. 5F
• Messenger RNA vaccination and B-cell responses in NSCLC patients. (Abstract #2573)
  Martin Sebastian

Brd. 5G
• Adoptive cell therapy for melanoma patients using tumor-infiltrating lymphocytes, lymphodepleting chemotherapy, and low-dose interleukin-2. (Abstract #2574)
  Eva Ellebaek

Brd. 5H
• Bispecific Fynomer-antibody fusion proteins targeting two epitopes on HER2 (Abstract #2575)
  Frederic Mourlane

Brd. 6A
• A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. (Abstract #2576)
  Taofeek Kunle Owonikoko

Brd. 6B
• Vaccine therapy with tumor-specific mutated ras peptides and IL-2, GM-CSF, or both in adult patients with solid tumors. (Abstract #2577)
  Osama E. Rahma

Brd. 6C
• An alternative clinical trial design for early cancer vaccine development to phase 3+3 design. (Abstract #2578)
  Emily Gammoh
• Targeting hyaluronan (HA) in tumor stroma: A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of pegylated hyaluronidase (PEGPH20) in patients with solid tumors. (Abstract #2579)
  
  Mitesh J. Borad

• Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors. (Abstract #2580)
  
  Paolo Andrea Zucali

• A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable metastatic colorectal carcinoma. (Abstract #2581)
  
  Aradeep Chatterjee

• Randomized phase II trial of multipeptide vaccination with or without a single pre-vaccine dose of denileukin diftitox in advanced melanoma. (Abstract #2582)
  
  Thomas Gajewski

• Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors. (Abstract #2583)
  
  Eric Angevin

• Association of humoral antitumor response with clinical benefit in catumaxomab-treated malignant ascites patients: Results from a phase IIIb study. (Abstract #2584)
  
  Peter Ruf

• Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial. (Abstract #2585)
  
  Michael Morse

• Effect of modulation of the hostile tumor microenvironment through adoptive transfer of IL-12 expressing MUC-16 targeted T cells on ovarian tumors in vivo. (Abstract #2586)
  
  Alena A. Chekmasova

• Development of an assay based on SOMAmer affinity reagents that detects drug-unbound serum EGFR in the presence of cetuximab and panitumumab. (Abstract #2587)
  
  Noh Jin Park

• Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients. (Abstract #2588)
  
  Neil Lorne Berinstein

• Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (Abstract #2589)
  
  Rachel Lubong Sabado

• A phase I study of lapatinib (LPT) and cetuximab (CTX) in patients with CTX-sensitive solid tumors. (Abstract #2590)
  
  John F. Deeken
• Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. (Abstract #2591)
  
  Whitney Paige Caron

Brd. 8A
• Phase I study of docetaxel injection concentrate for nano-dispersion (DICN), a novel polysorbate 80-free formulation of docetaxel. (Abstract #2592)
  
  Minish Mahendra Jain

Brd. 8B
• Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs). (Abstract #2593)
  
  Paul Hamberg

Brd. 8C
• Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. (Abstract #2594)
  
  Sameer Doshi

Brd. 8D
• Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of PF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors. (Abstract #2595)
  
  Erjian Wang

Brd. 8E
• Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. (Abstract #2596)
  
  Nienke A.G. Lankheet

Brd. 8F
• Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships. (Abstract #2597)
  
  Karthik Venkatakrishnan

Brd. 8G
• Docetaxel pharmacogenetics: The influence of RXRa and HNF4α genetic variations on docetaxel disposition in Asian nasopharyngeal carcinoma patients. (Abstract #2598)
  
  Sin Chi Chew

Brd. 8H
• Effects of metformin and sulfonylureas on overall and colorectal cancer-specific mortality. (Abstract #2599)
  
  Susan Spillane

Brd. 9A
• Antibody-dependent cell-mediated cytotoxicity (ADCC) evolution under treatment by cetuximab and links with treatment outcome in colorectal cancer (CRC) patients. (Abstract #2600)
  
  Marco Carlo Merlano

Brd. 9B
• Biomarkers of vincristine neuropathy in Kenyan children. (Abstract #2601)
  
  Jodi L Skiles
• Is cigarette smoke associated with increased catabolism of gemcitabine in patients with advanced solid tumors? (Abstract #2602)
  
  **Meaghan Working O’Malley**

• Dovitinib (TKI258): Exploration of pharmacokinetics and pharmacodynamics (PK/PD) for dose and regimen consideration. (Abstract #2603)
  
  **Samira Merali Garonzik**

• A randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. (Abstract #2604)
  
  **David C Currow**

• Vectorized gene therapy of liver tumors: Safety and proof of concept of TG4023 (MVA-FCU1)/5-FC combination. (Abstract #2605)
  
  **Faress Husseini**

• The role of phase I clinical trials in advanced malignant melanoma: Retrospective analysis of CTEP-sponsored trials 1995-2011. (Abstract #2606)
  
  **Jason John Luke**

• Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation. (Abstract #2607)
  
  **Eiki Ichihara**

• Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials. (Abstract #2608)
  
  **Chara Stavraka**

• Should patients with extrapulmonary small cell carcinoma receive prophylactic cranial irradiation? An Irish experience. (Abstract #2609)
  
  **Jarushka Naidoo**

• Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC). (Abstract #2610)
  
  **Sai-Hong Ignatius Ou**

• Evaluation of utility of pharmacokinetic studies in phase I combination trials. (Abstract #2611)
  
  **Kehua Wu**

• Effect of baseline QTc interval prolongation on oncology clinical trial enrollment. (Abstract #2612)
  
  **Carolina Moreno**

• An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. (Abstract #TPS2613)
  
  **Charles G. Drake**
A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma. (Abstract #TPS2614)

Hans J. Hammers

A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer. (Abstract #TPS2615)

Scott N. Gettinger

A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate. (Abstract #TPS2616)

Roel Peter Funke

First-in-human phase I trial of NHS-IL12 in advanced solid tumors. (Abstract #TPS2617)

Joseph W. Kim

Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors. (Abstract #TPS2618)

Paul Haluska

A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL). (Abstract #TPS2619)

Marco L. Davila

A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors. (Abstract #TPS2620)

Erica Jackson

Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (Abstract #TPS2621)

Ronald B. Natale

Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody. (Abstract #TPS2622)

Shruti Agrawal

Session Title: Developmental Therapeutics - Experimental Therapeutics
Session Type: General Poster Session
Time: 8:00 AM - 12:00 PM
Location: S Hall A2

A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors. (Abstract #3034)

David S. Mendelson

The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies. (Abstract #3035)

Sandra Heskamp
• Response of nonenhancing regions in glioblastoma to VEGF-signaling inhibitor cediranib correlates with tumor infiltration. (Abstract #3036)
  
  Summer A Fakhro

Brd. 12C
• Phase I study of vandetinib in combination with gemcitabine and oxaliplatin in advanced solid malignancies. (Abstract #3037)
  
  Peng Wang

Brd. 12D
• Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors. (Abstract #3038)
  
  Jin Li

Brd. 12E
• MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study. (Abstract #3039)
  
  Christian K. Kollmannsberger

Brd. 12F
• First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors. (Abstract #3040)
  
  Jian-Ming Xu

Brd. 12G
• Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors. (Abstract #3041)
  
  Kathleen N. Moore

Brd. 12H
• Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients. (Abstract #3042^)
  
  Shawn D Spencer

Brd. 13A
• A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC). (Abstract #3043)
  
  Fatima H Karzai

Brd. 13B
• SORAVE: Phase I study for the treatment of relapsed solid tumors with the combination of sorafenib and everolimus. (Abstract #3044)
  
  Lucia Nogova

Brd. 13C
• Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. (Abstract #3045)
  
  Takashi Seto

Brd. 13D
• A dose-escalation phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 28 days on/14 days off schedule. (Abstract #3046)
  
  Juneko E. Grilley-Olson

Brd. 13E
• Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer (TNBC). (Abstract #3047)
  
  Cynthia X. Ma
Brd. 13F
• Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. (Abstract #3048)
  
  L Rhoda Molife

Brd. 13G
• A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies. (Abstract #3049)
  
  Leonard Joseph Appleman

Brd. 13H
• Developing rational drug combination strategies for PARP inhibitors. (Abstract #3050)
  
  Farah Rehman

Brd. 14A
• Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single-agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595). (Abstract #3052)
  
  Mario Campone

Brd. 14B
• Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase. (Abstract #3051)
  
  Avinash Gupta

Brd. 14C
• Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors. (Abstract #3053)
  
  Geoffrey Shapiro

Brd. 14D
• A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt). (Abstract #3054)
  
  Shannon Leigh Huggins-Puhalla

Brd. 14E
• Using proton MRSI to predict response to vorinostat treatment in recurrent GBM. (Abstract #3055)
  
  Hyunsuk Shim

Brd. 14F
• A phase I/II study to evaluate the ability of decitabine and panobinostat to improve temozolomide chemosensitivity in metastatic melanoma. (Abstract #3056)
  
  Chang Xia

Brd. 14G
• Testing targeted demethylation to overcome resistance to epidermal growth factor receptor (EGFR) blocking agents in wild-type (wt) KRAS metastatic colorectal cancer patients (mCRC). (Abstract #3057)
  
  Ignacio Garrido-Laguna

Brd. 14H
• A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies. (Abstract #3058)
  
  Amy Patricia Moore
• Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors. (Abstract #3059)

  Antonio Calles

• A phase I study of EP-100, a luteinizing hormone releasing hormone (LHRH) ligand conjugated to a synthetic cytolytic peptide in patients with advanced refractory LHRH-receptor (R)-expressing tumors. (Abstract #3060)

  Ramesh K. Ramanathan

• Improved sorafenib activity on hepatocellular carcinoma in Notch3 silenced in vivo and in vitro models. (Abstract #3061)

  Michele Baglioni

• Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy. (Abstract #3062)

  Maria Alsina

• Evaluation of toxicities of target therapy phase I and II trials on glioblastoma multiforme patients treated by curative radiotherapy: A meta-analysis. (Abstract #3063)

  Marcos Antonio Santos

• Microarray genomic expression (MAGE)-based therapy for heavily pretreated patients with metastatic solid tumors. (Abstract #3064)

  Joseba Rebollo

• High concordance for MammaPrint 70 genes by RNA next generation sequencing. (Abstract #3065)

  Lorenza Mittempergher

• Feasibility to obtain a chemogram in circulating tumorigenic cells to guide further treatments in refractory solid tumors. (Abstract #3066)

  Antonio Cubillo

• ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study. (Abstract #3067)

  Carla Kurkjian

• Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment. (Abstract #3068)

  Elena Garralda

• CD30 expression in nonlymphomatous malignancies. (Abstract #3069)

  Jeff Porter Sharman

• OM-RCA-01, an FGFR1 specific humanized antibody for the treatment of renal cell carcinoma (RCC). (Abstract #3070)

  Ilya Tsimafeyeu
• Clinical significance of PRL-3 genomic amplification/expression profiles and preclinical study of PRL-3 inhibitor in human gastrointestinal cancers. (Abstract #3071)
  Keishi Yamashita

• Effect of MDV3100, a novel androgen receptor signaling inhibitor, on cell proliferation and tumor size in an apocrine breast cancer xenograft model. (Abstract #3072)
  Sebastián Bernales

• Inhibition of autophagy: Phase I safety, tolerability, and pharmacokinetics (PK) of hydroxychloroquine (H) in combination with vorinostat (V) in patients with advanced solid tumors. (Abstract #3073)
  Devalingam Mahalingam

• Targeted therapies for the treatment of non-small cell lung cancer: Bull’s eye or missed target? (Abstract #3074)
  Shakun M. Malik

• Translational assessment of the efficacy of CPI-613 against pancreatic cancer in animal models versus patients with stage IV disease. (Abstract #3075)
  Avi S. Retter

• A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors. (Abstract #3076)
  Tae Min Kim

• Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors. (Abstract #3077)
  Alessandra Di Bacco

• Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study. (Abstract #3078)
  John Sarantopoulos

• Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors. (Abstract #3079)
  Toshihiko Doi

• A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595). (Abstract #3080)
  Gianluca Del Conte

• A phase I study to assess oral bioavailability of a novel oral soft gelatin capsule formulation of rigosertib (ON 01910.Na) under fasted and fed conditions in patients with myelodysplastic syndromes. (Abstract #3081)
  Azra Raza
• A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). (Abstract #3082)
  
  Sue Richter

• A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). (Abstract #3083)
  
  Melissa Lynne Johnson

• Phase I and pharmacokinetic study of farletuzumab in solid tumors. (Abstract #3084)
  
  Yasutsuna Sasaki

• Phase IB study of an all-oral chemotherapy regimen, tesetaxel plus capecitabine, in patients with advanced solid tumors. (Abstract #3085)
  
  Michael Gary Martin

• Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors. (Abstract #3086)
  
  Dan Zhou

• Phase I study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors. (Abstract #3087)
  
  Khanh Tu Do

• A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors. (Abstract #3088^)
  
  Hiroya Takiuchi

• Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK- and ROS1-driven cancers. (Abstract #3090)
  
  Ateeq Ahmad

• BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamycin-induced AKT activation. (Abstract #3092)
  
  Paul J. Adam

• Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors. (Abstract #3093)
  
  Sanjay Goel
• A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. (Abstract #3094)
  
  John S. Kauh

• A phase I trial of the mTOR inhibitor temsirolimus (TEM) in combination with capecitabine (CAP) in patients with advanced malignancies. (Abstract #3095)
  
  Michael J. Pishvaian

• Phase I study of sirolimus plus gemcitabine in patients with advanced solid tumors: A Spanish Group for Research on Sarcomas (GEIS) study. (Abstract #3096)
  
  Juan Martin Liberal

• The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. (Abstract #3097)
  
  Hendrik-Tobias Arkenau

• A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers. (Abstract #3098)
  
  Daniel Shao-Weng Tan

• Meta-analysis on the relationship between everolimus exposure and safety and efficacy. (Abstract #3099)
  
  Dalila B. Sellami

• A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors. (Abstract #3100)
  
  Richard D Baird

• A phase I study of the gamma-secretase inhibitor RO4929097 and capecitabine in refractory solid tumors. (Abstract #3101)
  
  Noelle K. LoConte

• A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC). (Abstract #3103)
  
  Dustin A. Deming

• Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors. (Abstract #3104)
  
  Antoine Hollebecque

• A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). (Abstract #3105)
  
  Andrew H. Ko

• NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials. (Abstract #3106)
  
  Vinu Madhusudannair
• First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors. (Abstract #3107^)
  
  **Hesham M. Amin**

• Phase I trials of PS-341 (bortezomib, B) in combination with topotecan (T) in advanced solid tumors: A potential pharmacokinetic (PK) interaction. (Abstract #3108)
  
  **Robert Morgan**

• Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates. (Abstract #TPS3109)
  
  **Hannah M. Linden**

• Design of a phase I clinical trial with PNT2258, a novel DNA interference oligonucleotide (DNAi), in patients with advanced solid tumors. (Abstract #TPS3110)
  
  **Drew Warren Rasco**

• A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors. (Abstract #TPS3111)
  
  **Donald A. Richards**

• A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma. (Abstract #TPS3112)
  
  **Janice M. Mehnert**

• First-in-human phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors. (Abstract #TPS3113)
  
  **Laura E. Strong**

• Phase Ia/b study of combination carboplatin, paclitaxel, and ridaforolimus in patients with solid, endometrial, and ovarian cancers. (Abstract #TPS3114)
  
  **Hye Sook Chon**

• BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. (Abstract #TPS3115)
  
  **Matthias Scheffler**

• A dose escalation, single arm, phase Ib-II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme. (Abstract #TPS3116)
  
  **Mohamad Adham Salkeni**

• A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer. (Abstract #TPS3117)
  
  **Shabina Roohi Ahmed**
Phase Ib combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors. (Abstract #TPS3118)

Jeffrey R. Infante

Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: General Poster Session
Time: 8:00 AM - 12:00 PM
Location: S Hall A2

Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial. (Abstract #3534)

Timothy Jay Price

Final results of study 20050181: A randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the second-line treatment (tx) of metastatic colorectal cancer (mCRC). (Abstract #3535)

Alberto F. Sobrero

Do we need adjuvant therapy in rectal cancer with complete pathologic response (ypT0N0) after induction chemoradiation and laparoscopic mesorectal excision? (Abstract #3536)

Verónica Pereira

Patterns of chemotherapy (CT) use in a U.S.-wide population-based cohort of patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #3537)

Thomas Adam Abrams

Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. (Abstract #3538)

Per Pfeiffer

Phase I study of EMD 525797 (DI17E6), an antibody targeting αvβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-raf wild-type metastatic colorectal cancer. (Abstract #3539)

Elena Elez

Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan. (Abstract #3540)

Carlotta Antoniotti

Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer. (Abstract #3541)

Ralf Hofheinz

Utilization and outcomes of primary tumor surgery for stage IV colon cancer in the United States: A population-based study. (Abstract #3542)

Yvonne Sada
• Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). (Abstract #3543)
  
  Saifuddin M. Kasubhai

Brd. 23G

• Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly.
  (Abstract #3544)
  
  Kanwal Pratap Singh Raghav

Brd. 23H

• Comparative effectiveness of sphincter-sparing surgery (SSS) versus abdomino-perineal resection (APR) in rectal cancer: Patient-reported outcomes (PROs) from NSABP R-04. (Abstract #3545)
  
  Patricia A. Ganz

Brd. 24A

• KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab.
  (Abstract #3546)
  
  Marta Schirripa

Brd. 24B

• First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228).
  (Abstract #3547)
  
  Francis Levi

Brd. 24C

• Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. (Abstract #3548)
  
  Line Schmidt Tarpgaard

Brd. 24D

• Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. (Abstract #3549)
  
  Fotios Loupakis

Brd. 24E

• Adjuvant chemotherapy (ACT) in stage II colon cancer (CC) in patients with Lynch syndrome.
  (Abstract #3550)
  
  Karsten Schulmann

Brd. 24F

• An 18-gene blood-based IVD test for colorectal cancer early detection with high sensitivity and specificity. (Abstract #3551)
  
  Ye Xu

Brd. 24G

• Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC). (Abstract #3552)
  
  Mark Kozloff

Brd. 24H

• Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. (Abstract #3553)
  
  Virginia Alonso-Espinaco
• Prognostic impact of miR-146 polymorphism in patients with resected colorectal cancer. (Abstract #3554)
  
  Jong Gwang Kim

• Phase II study of panitumumab (P) in combination with FOLFOXIRI as first-line treatment of metastatic colorectal cancer (mCRC): Activity in molecularly selected patients (pts). (Abstract #3555)

  Sara Lonardi

• Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. (Abstract #3556)

  George J. Chang

• Post-progression survival (PPS) according to treatment line, type, and time in phase III trials in advanced colorectal cancer (ACC). (Abstract #3557)

  Marc E. Buyse

• Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901). (Abstract #3558)

  Kazuma Kobayashi

• Impact of body mass index (BMI) and weight changes on recurrence and survival in stage III colon cancer (CC). (Abstract #3560)

  Joanna Vergidis

• Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer. (Abstract #3561)

  Van Karlyle Morris

• Chemotherapy plus cetuximab in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: A pooled analysis of the CRYSTAL and OPUS studies. (Abstract #3562)

  Claus-Henning Kohne

• Evaluation of FDG-PET in pretreatment staging in locally advanced rectal cancer: A prospective study. (Abstract #3563)

  Jose G. Guillem

• Association study of the let-7 microRNA-binding site polymorphism in 3' untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147. (Abstract #3564)

  Dan Sha

• Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study. (Abstract #3565)

  Suayib Yalcin
Prognostic significance of lymph node retrieval in localized rectal cancer (RC): A registry analysis of 8,964 patients (pts). (Abstract #3566)
Amandeep Gill

Implications of generating genetic test results for colon cancer in the international, population-based colon cancer family registry. (Abstract #3567)
Louise A. Keogh

Association of microsatellite instability with prognosis in the pathologic N2 colon cancer patients treated with adjuvant FOLFOX chemotherapy. (Abstract #3568)
Jeong Eun Kim

Short-term clinical outcomes from a randomized controlled trial to evaluate laparoscopic versus open complete mesocolic excision for stage II,III colorectal cancer (CRC): Japan Clinical Oncology Group study JCOG0404 (NCT00147134). (Abstract #3569)
Yusuke Nishizawa

Phase II study of dacarbazine for metastatic colorectal cancer with determined MGMT status. (Abstract #3570)
Alessio Amatu

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer. (Abstract #3571)
Mercedes Martinez Villacampa

Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC). (Abstract #3572)
Jeremy David Shapiro

The relationship between microRNA-126 and maintenance therapy with bevacizumab after bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results of the phase III Nordic ACT trial NCT00598156 translational study. (Abstract #3573)
Torben Hansen

Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data. (Abstract #3574)
Julien Taïeb

Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers. (Abstract #3575)
Vlad Calin Popovici

Prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1) in colorectal cancer (CRC) patients (Pts): A pooled analysis of 1,024 stage II/III pts. (Abstract #3576)
Nils Brünner
• Is conversion to resection possible with hepatic arterial infusion (HAI) and systemic (SYS) even in previously treated patients (pts) with unresectable colorectal liver metastases (UnCLM)?

_Nancy E. Kemeny_

Brd. 31G

• The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA). (Abstract #3578)

_Hans-Joachim Schmoll_

Brd. 31H

• Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl). (Abstract #3579)

_Josep Tabernero_

Brd. 32A

• Mechanisms mediating the negative interaction between oxaliplatin (Ox) and epidermal growth factor receptor (EGFR) inhibitors in patients (pts) with KRAS mutant (MT) colorectal cancer (CRC). (Abstract #3580)

_Daniel J. Freeman_

Brd. 32B

• Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). (Abstract #3581)

_Marc Peeters_

Brd. 32C

• A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS-wild type tumors who progressed on prior standard dose cetuximab and irinotecan. (Abstract #3582)

_Ahmad Ali Fora_

Brd. 32D

• Is there any significant difference between tumor regression grade systems of rectal cancer? (Abstract #3583)

_Attaphorn Trakarnsanga_

Brd. 32E

• Association of genetic variants in obesity-related genes with tumor recurrence in stage II/III colon cancer. (Abstract #3584)

_Robert D. Ladner_

Brd. 32F

• FOLFOXIRI plus bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. (Abstract #3585)

_Lisa Salvatore_

Brd. 32G

• Neoadjuvant capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. (Abstract #3586)

_Carlos Fernandez-Martos_

Brd. 32H

• Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data. (Abstract #3587)

_Sriram Sathyanarayanan_
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial. (Abstract #3588)

Dominik Paul Modest

Examining the effects of metformin on survival outcome in stage II/III colorectal cancer patients with diabetes mellitus. (Abstract #3589)

Guek Eng Lee

U.S. patients receiving resin90Y microspheres for unresectable colorectal liver metastases: A multicenter study of 506 patients. (Abstract #3590)

Andrew S. Kennedy

First-line chemotherapy plus cetuximab in patients grouped according to prognostic risk factors: Analysis of the CRYSTAL and OPUS studies. (Abstract #3591)

Gunnar Folprecht

A UGT1A1 *28 and *6 genotype-directed phase I study of irinotecan plus infusional leucovorin and 5-fluorouracil (sLV5FU2) in patients with previously untreated metastatic colorectal cancer (mCRC). (Abstract #3592)

Yong Sang Hong

Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. (Abstract #3593)

Satoshi Yuki

Functional SNPs in vascular endothelial growth factor (VEGF-A) and overall survival (OS) in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). (Abstract #3594)

Janet E. Murphy

Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08). (Abstract #3595)

Roger Von Moos

Treating patients with colorectal liver metastasis: A national decision-making analysis to understand choice of therapy. (Abstract #3596)

Timothy M Pawlik

Genetic variants of kinases suppressors of ras in KRAS-BRAF wild-type metastatic colorectal cancer patients treated with cetuximab and irinotecan. (Abstract #3597)

Leonor Benhaim

Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. (Abstract #3598)

Zhi-Yu Chen
Brd. 34D
• The effect of deprivation on uptake and outcomes in a population-based FOBt colorectal cancer screening program. (Abstract #3599)
  
  David Mansouri

Brd. 34E
• HER2 status in locally advanced rectal cancer and metachronous metastases: Opportunity for a new therapeutic approach? (Abstract #3600)
  
  Lena-Christin Conradi

Brd. 34F
• Cost-effectiveness analysis per life-year gained based on predictors of response for first-line metastatic colorectal cancer therapy in Spain. (Abstract #3601)
  
  Cristobal Belda-Iniesta

Brd. 34G
• Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from a phase III trial (VELOUR). (Abstract #3602)
  
  Florence Joulain

Brd. 34H
• Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS. (Abstract #3603)
  
  Ulrich Robert Mansmann

Brd. 35A
• Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. (Abstract #3604)
  
  Pierre Oliver Bohanes

Brd. 35B
• Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-FU, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: A trial of the Eastern Cooperative Oncology Group (E3204). (Abstract #3605)
  
  Steven J. Cohen

Brd. 35C
• Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer. (Abstract #3606)
  
  Gun Min Kim

Brd. 35D
• Six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III (Dukes’ C) colon cancer: Initial safety report for the open-label randomized phase III study (JFMC37-0801). (Abstract #3607)
  
  Katsuyuki Kunieda

Brd. 35E
• Effect of postoperative complications on adjuvant chemotherapy use in stage III colon cancer. (Abstract #3608)
  
  Ryan P Merkow

Brd. 35F
• Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. (Abstract #3609)
  
  Francois Cauchy
• A population-based study of the effect of FDG PET/CT in the management of liver-limited colorectal adenocarcinoma (CRC) metastases. (Abstract #3610)
  
  Maria Yi Ho

• Clinical utility of the preoperative Glasgow prognostic score in patients undergoing potentially curative resection for colorectal cancer. (Abstract #3611)

  Donald C. Mcmillan

• Does multiple mutational analysis of the EGFR pathway have a prognostic role in advanced colorectal cancer (CRC)? (Abstract #3612)

  Luisa Foltran

• Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads transarterial chemoembolization (DEBIRI-TACE): A multi-institute phase II study in resectable metastases. (Abstract #3613)

  Robert Peter Jones

• Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): Pooled analysis from randomized controlled trials (RCTs). (Abstract #3614)

  Niall Christopher Tebbutt

• Association of HER2 and IGF1 germline polymorphisms with outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR) with or without cetuximab (CB): The EPIC experience. (Abstract #3615)

  Dongyun Yang

• Incidence and prognostic impact of KRAS and BRAF mutations in patients undergoing liver surgery for colorectal metastases. (Abstract #3616)

  Georgios Karagkounis

• Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). (Abstract #3617)

  Jeff A. Sloan

• Pharmacogenetic profiling for oxaliplatin-based adjuvant chemotherapy (CT) benefit in stage II-III colon cancer (CC) patients: A GEMCAD study. (Abstract #3618)

  Jaime Feliu

• Comparison of incidence and patterns of recurrence in colon cancer (Cca) treated by sentinel lymph node (SLN) mapping (M) versus conventional surgery. (Abstract #3619)

  Mohammed Saifullah Shaik

• Effect of perioperative complications on recurrence and survival after resection of hepatic colorectal metastases: Analysis of data from a randomized controlled trial. (Abstract #3620)

  Camilo Correa-Gallego

• Colorectal cancer characteristics and outcomes in patients less than age 50: A comparison of an urban university hospital with the NCI SEER database. (Abstract #3621)

  Edith P. Mitchell
• Novel colon cancer tumor suppressor gene, β-defensin 1, to predict recurrence in patients with stage II and III colon cancer. (Abstract #3622)
  
  Melissa Janae Labonte

• Clinicopathologic and molecular associations of PIK3CA and PTEN mutation in colorectal cancer. (Abstract #3623)
  
  Fiona Lee Day

• Methylation of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer. (Abstract #3624)
  
  Hyun-Jung Lee

• Impact of “poorly differentiated clusters” in primary lesion as a novel prognostic indicator in colorectal liver metastasis. (Abstract #3625)
  
  Tsuyoshi Konishi

• Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer. (Abstract #3626)
  
  Thomas H. Cartwright

• Effect of BSA dosing on 5-FU exposure among colorectal cancer patients depending on their gender and age. (Abstract #3627)
  
  Abebe Haregewoin

• Use of gene set analysis (GSA) for molecular classification of responders and nonresponders to FOLFOX therapy in colorectal cancer (CRC). (Abstract #3628)
  
  Stephen Yip

• Phase II trial evaluating a 12-week regimen of interdigitating FOLFOX chemotherapy plus pelvic chemoradiation for the simultaneous treatment of primary and metastatic rectal cancer. (Abstract #3629)
  
  Michael Michael

• Evaluation of the prognostic utility of miRNA and multiple genetic markers in stage IIA colon cancer. (Abstract #3630)
  
  Elizabeth Mambo

• A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC). (Abstract #3631)
  
  Manish R. Patel

• Surgical resection and peri-operative chemotherapy for colorectal cancer (CRC) liver metastases in routine clinical practice: A population-based outcomes study. (Abstract #3632)
  
  Christopher M. Booth

• Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of the Val d’Aurelle Center. (Abstract #3633)
  
  Emmanuelle Samalin
Br. 38G
• A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780). (Abstract #TPS3634)
  Axel Grothey

Br. 38H
• MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC). (Abstract #TPS3635^)
  Sachdev P. Thomas

Br. 39A
• TRICC-c: BIBF 1120 versus placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)—A multicenter, randomized phase II trial in progress. (Abstract #TPS3636)
  Andreas Berger

Br. 39B
• The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC). (Abstract #TPS3637)
  Andres Cervantes-Ruiperez

Br. 39C
• A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer. (Abstract #TPS3638)
  John Marshall

Br. 39D
• Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110 / ML22011 randomized, phase III trial. (Abstract #TPS3639)
  Clemens Albrecht Giessen

Br. 39E
• A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. (Abstract #TPS3640)
  Johanna C. Bendell

Br. 39F
• A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (Abstract #TPS3641^)
  Carl Christoph Schimanski

Br. 39G
• FOLFIRI plus 5 mg/kg of bevacizumab versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE Study). (Abstract #TPS3642)
  Masato Nakamura
ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer. (Abstract #TPS3643)

Jonathan Fawcett

Session Title: Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Time: 8:00 AM - 12:00 PM
Location: S Hall A2

Brd. 40A
• Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. (Abstract #4034)
  Helmut Oettle

Brd. 40B
• Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan. (Abstract #4035)
  Akira Fukutomi

Brd. 40C
• Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study). (Abstract #4036)
  Michel Ducreux

Brd. 40D
• Incidence and characterization of venous thromboembolic events (VTE) in patients with pancreatic cancer: Effect of timing of VTE on survival. (Abstract #4037)
  Maithili A Shethia

Brd. 40E
• A pooled analysis of phase II trials of gemcitabine (GEM)-containing doublets plus bevacizumab (BEV): Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer (APC)? (Abstract #4038)
  Katherine Van Loon

Brd. 40F
• Baseline albumin (b-alb) as a potential predictive biomarker for the efficacy of bevacizumab (B) therapy (tx) in patients (pts) with advanced pancreas cancer (APCA): A comparative analysis. (Abstract #4039)
  Ludmila Katherine Martin

Brd. 40G
• Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. (Abstract #4040)
  Rafael Alvarez-Gallego

Brd. 40H
• Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma. (Abstract #4041)
  Stefan Hubert Boeck
• A phase III trial of ganitumab (GAN, AMG 479) with gemcitabine (G) as first-line treatment (tx) in patients (pts) with metastatic pancreatic cancer (MPC): An analysis of safety from the GAMMA trial (GEM and AMG 479 in Metastatic Adenocarcinoma of the Pancreas). (Abstract #4042)

Charles S. Fuchs

• Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results. (Abstract #4043)

Allyson J. Ocean

• Evaluation of predictive factors for thromboembolic events in patients with advanced pancreatic cancer: Evaluation of the CONKO-004 (PROSPECT) study cohort. (Abstract #4044)

Uwe Pelzer

• A phase II multi-institutional study to evaluate gemcitabine and fractionated stereotactic body radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma. (Abstract #4045)

Joseph M. Herman

• Multicenter retrospective analysis of systemic chemotherapy for advanced poorly differentiated neuroendocrine carcinoma of the digestive system. (Abstract #4046)

Nozomu Machida

• Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis. (Abstract #4047)

Timothy J. Hobday

• A phase I study of nab-paclitaxel (A), gemcitabine (GEM), and capecitabine (X) in patients with metastatic pancreatic adenocarcinoma (MPA). (Abstract #4048)

Thach-Giao Truong

• Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. (Abstract #4049)

Jeffrey M Hardacre

• A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results. (Abstract #4050)

Jean-Luc Van Laethem

• Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. (Abstract #4051)

Rachna T. Shroff

• A phase IIB study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic GI Cancer Consortium (AGICC) study. (Abstract #4052)

Lawrence P. Leichman
• International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer. (Abstract #4053)
  
  Franck Bonnetain

Brd. 42E
• Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). (Abstract #4054)
  
  Milind M. Javle

Brd. 42F
• A randomized phase III multi-institutional study of TNFerade biologic with 5-FU and radiotherapy for locally advanced pancreatic cancer: Final results (Abstract #4055)
  
  Aaron Tyler Wild

Brd. 42G
• M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer. (Abstract #4056)
  
  Birgit Corinna Schultes

Brd. 42H
• Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). (Abstract #4057)
  
  Maeve A Lowery

Brd. 43A
• Benefits of platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series. (Abstract #4058)
  
  Olusola Olusesan Faluyi

Brd. 43B
• Inequal benefits from regionalization of cancer care: The pancreatic cancer surgery paradigm. (Abstract #4059)
  
  Theodore P. McDade

Brd. 43C
• Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. (Abstract #4060)
  
  Cathy Eng

Brd. 43D
• Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. (Abstract #4061)
  
  David Ilson

Brd. 43E
• A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). (Abstract #4062)
  
  Carolyn E Reed

Brd. 43F
• Bisphosphonates and esophageal cancer: A RADAR report. (Abstract #4063)
  
  Beatrice J. Edwards

Brd. 43G
• Combined analysis of randomized controlled trial (RCT) and patient-preference trial (PPT) evaluating second-line chemotherapy (SLC) in advanced gastric cancer (AGC). (Abstract #4064)
  
  Soonil Lee
• Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): Findings from the German noninterventional observational study HerMES. (Abstract #4065)

  Susanna Hegewisch-Becker

• Does in-house availability of multidisciplinary teams increase survival in upper GI cancer? (Abstract #4066)

  Christian Kersten

• Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. (Abstract #4067)

  Kohei Shitara

• Measuring transcripts of components of the BRCA1 DNA repair pathway, components of the hippo-YAP pathway, β-TrCP, HER2, AEG-1, EZH2 and other genes in advanced gastric cancer. (Abstract #4068)

  Jia Wei

• Customization of treatment for patients with esophageal adenocarcinoma (EAC) who achieve clinical complete response (CCR) after chemoradiation using initial standardized uptake value (iSUV) of 18F-fluorodeoxyglucose PET. (Abstract #4069)

  Akihiro Suzuki

• Investigatory study of biomarkers for gastric cancer based on a cDNA bank. (Abstract #4070)

  Takashi Oshima

• Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). (Abstract #4071)

  Emmanuel Mitry

• NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma. (Abstract #4072)

  Christoph Schulz

• Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study. (Abstract #4073)

  Jinming Yu

• Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie. (Abstract #4074)

  Ewald Woell

• Post-recurrence survival in patients with previously resected esophageal adenocarcinoma (EAC). (Abstract #4075)

  Mark Lewis
• Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: A clinical-biological risk stratification model. (Abstract #4076)

  Emilio Bria

• Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer. (Abstract #4077)

  Mary Frances Mulcahy

• Outcome of 58 trimodality-eligible esophagogastric cancer (EC) patients who achieved clinical complete response (cCR) after preoperative chemoradiation but then declined surgery. (Abstract #4078)

  Takashi Taketa

• Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment. (Abstract #4079)

  Rosa Gallego

• Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with or without docetaxel, in elderly patients with locally advanced esophagogastric cancer. (Abstract #4080)

  Sylvie Lorenzen

• Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study. (Abstract #4081)

  Kun-Huei Yeh

• A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. (Abstract #4082)

  Kei Muro

• Interim safety results from a phase II/III trial with 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO. (Abstract #4083)

  Ulrike Koock

• Assessment of the 7th edition of the AJCC classification and a proposal of a new classification in patients with gastric cancer undergoing D2 gastrectomy. (Abstract #4084)

  Vincenzo Catalano

• Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study. (Abstract #4085)

  Thomas M. O'Dorisio

• Association of clinical complete response (cCR) after preoperative chemoradiation and pathological complete response (pathCR) in patients with gastroesophageal cancer (GEC) and indispensability of trimodality therapy (TMT). (Abstract #4086)

  Naga K Sucharita Cheedella
• Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma. (Abstract #4087)
  Simon Pernot

• Prognostic value of lemur tyrosine kinase-3 (LMTK3) polymorphism in Japanese (J) patients (PTS) with localized gastric adenocarcinoma (GAC). (Abstract #4088)
  Afsaneh Barzi

• Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: Spanish results of the HER-EAGLE study. (Abstract #4089)
  Lourdes Gomez

• A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3. (Abstract #4090)
  Salah-Eddin Al-Batran

• Nooadjuvant chemoradiotherapy with 5-fluorouracil-cisplatin combined with cetuximab in patients with resectable locally advanced esophageal carcinoma: A prospective phase I/II trial (FFCD-PRODIGE 3)—Preliminary phase II results. (Abstract #4091)
  Laetitia Dahan

• Positive association of gastric cancer surgery outcome with surgeon specialization in a Shanghai high-volume general hospital. (Abstract #4092)
  Zhenbin Shen

• Randomized phase II study of preoperative concurrent chemoradiotherapy with or without induction chemotherapy with S-1 and oxaliplatin in patients with resectable esophageal cancer. (Abstract #4093)
  Dok Hyun Yoon

• Multicenter phase II study combining panitumumab with chemoradiation followed by surgery for patients with operable esophageal cancer (PACT-study). (Abstract #4094)
  Sil Kordes

• Two-year follow-up of a phase II study on catumaxomab as part of a multimodal approach in primarily resectable gastric cancer. (Abstract #4095^)
  Carsten Bokemeyer

• A phase II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ) adenocarcinoma. (Abstract #4096)
  Syma Iqbal

• Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by oxaliplatin, folinic acid, 5-fluorouracil, and irinotecan (COFFI) in locally advanced or metastatic gastric cancer (MGC). (Abstract #4097)
  Gianluca Tomasello
• Lenalidomide for second-line treatment of advanced hepatocellular cancer (HCC): A Brown University Oncology Group phase II study. (Abstract #4098)  
  **Howard Safran**

Brd. 48B

• A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4099)  
  **Jennifer J. Knox**

Brd. 48C

• A phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma. (Abstract #4100^)  
  **Su Pin Choo**

Brd. 48D

• Serum folate, LINE-1 hypomethylation, and overall survival in a prospective cohort of hepatocellular carcinoma patients. (Abstract #4101)  
  **Abby B. Siegel**

Brd. 48E

• Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates. (Abstract #4102)  
  **Robin Katie Kelley**

Brd. 48F

• A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). (Abstract #4103)  
  **Ho Yeong Lim**

Brd. 48G

• A prospective cohort study using a Japanese nationwide survey to evaluate the therapeutic effects of surgery and percutaneous ablation for hepatocellular carcinoma. (Abstract #4104)  
  **Kiyoshi Hasegawa**

Brd. 48H

• Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4105)  
  **Ann Sing Lee**

Brd. 49A

• Blood signatures for early liver cancer detection in patients with chronic hepatitis B. (Abstract #4106)  
  **Choong-Chin Liew**

Brd. 49B

• Treatment of advanced or metastatic hepatocellular cancer (HCC): Final clinical results of a single-arm phase II study of bevacizumab and everolimus. (Abstract #4107)  
  **Gerhard Treiber**

Brd. 49C

• A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). (Abstract #4108)  
  **Thomas Cheung Yau**

Brd. 49D

• Biliary tract cancer: A large institutional experience. (Abstract #4109)  
  **Mairead Geraldine McNamara**
• Adjuvant chemotherapy following curative intent hepatectomy for intrahepatic cholangiocarcinoma: Results from a multi-institutional analysis of 575 patients. (Abstract #4110)

  Dario Ribero

• A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report. (Abstract #4111)

  Davendra Sohal

• Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147). (Abstract #4112)

  Andrew X. Zhu

• SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma. (Abstract #4113)

  Anthony B. El-Khoueiry

• Multiparametric quantitative functional MRI for assessing early changes in volumetric functional tumor burden in hepatocellular carcinoma treated by intra-arterial therapies. (Abstract #4114)

  Vivek Gowdra Halappa

• Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study. (Abstract #4115)

  Michael Bitzer

• Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. (Abstract #4117)

  Robert E. Martell

• Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). (Abstract #4118)

  Aaron Vinik

• PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)—NCT01280201. (Abstract #4119)

  Enrique Grande Pulido

• Merkel cell polyomavirus in gastrointestinal neuroendocrine tumors. (Abstract #4120)

  Salvatore Lorenzo Renne

• Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial. (Abstract #4121)

  Philippa Corrie

• RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe. (Abstract #4122)

  Marianne E. Pavel
• Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors. (Abstract #4123)
  
  Mohid Shakil Khan

• Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts. (Abstract #4124)
  
  Elaine Kilgour

• A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors. (Abstract #4125)
  
  Matthew Kulke

• Prevalence of functional tumors in neuroendocrine carcinoma: An analysis from the NCCN NET database. (Abstract #4126)
  
  Michael A. Choti

• Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). (Abstract #4127)
  
  Irfan Firdaus

• Prognostic relevance of circulating PlGF levels in patients with neuroendocrine tumors. (Abstract #4128)
  
  Christian Fischer

• Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality? The PRONET study group. (Abstract #4129)
  
  Jean-Yves Scoazec

• Patients with carcinoma of unknown primary and “colon cancer profile”: Clinicopathologic features and survival data. (Abstract #4130)
  
  Gauri R. Varadhachary

• Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. (Abstract #4131)
  
  Katherine Stemke Hale

• Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. (Abstract #4132)
  
  Ferry Eskens

• Methylguanine DNA methyl transferase (MGMT) expression to predict response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs). (Abstract #4133)
  
  Pascal Hammel

• Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trial. (Abstract #TPS4134)
  
  T.R. Jeffry Evans
• A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial. (Abstract #TPS4135)
  
  Charles S. Fuchs

• Gemcitabine with nab-paclitaxel in neoadjuvant treatment of pancreatic adenocarcinoma – GAIN-1 study. (Abstract #TPS4136)
  
  Neelam Vijay Desai

• PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. (Abstract #TPS4137)
  
  Yu Jo Chua

• PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the Arbeitsgemeinschaft internistische Onkologie (AIO). (Abstract #TPS4138)
  
  Kirstin Breithaupt

• A randomized, multicenter, double-blind, placebo (PBO)-controlled phase III study of paclitaxel (PTX) with or without ramucirumab (IMC-1121B; RAM) in patients (pts) with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum (PLT) and fluoropyrimidine (FP). (Abstract #TPS4139)
  
  Hansjochen Wilke

• Lapatinib in combination with ECF/x in EGFR1 positive first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071). (Abstract #TPS4140)
  
  Markus Hermann Moehler

• TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). (Abstract #TPS4141)
  
  Trevor Leong

• Postoperation chemotherapy with S1 and docetaxel in curatively resected gastric cancer of stage III (POST trial). (Abstract #TPS4142)
  
  Minkyu Jung

• ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, OGJ (oesophagogastric junction) or lower oesophageal adenocarcinoma. (Abstract #TPS4143)
  
  Elizabeth C Smyth

• A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer. (Abstract #TPS4144)
  
  Yelena Yuriy Janjigian
DOCTOR: A randomized phase II trial of pre-operative cisplatin, 5-fluorouracil and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. (Abstract #TPS4145)

Andrew Barbour

A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). (Abstract #TPS4146)

Andrew X. Zhu

An open-label, randomized phase II study comparing first-line treatment with dovitinib (TKI258) versus sorafenib in patients with advanced hepatocellular carcinoma. (Abstract #TPS4147)

Ann-Lii Cheng

Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (HCC) (SORAMIC). (Abstract #TPS4148)

Jens Ricke

Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial. (Abstract #TPS4149)

Ronnie Tung Ping Poon

TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC). (Abstract #TPS4150)

Tim Meyer

A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study. (Abstract #TPS4151)

Bruno Daniele

Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE). (Abstract #TPS4152)

James M. Burke

The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors. (Abstract #TPS4153)

Patrick Delavault

**Session Title:** Antibody Conjugates: Targeted Therapy Meets Chemotherapy in One Drug

**Session Type:** Education Session

**Time:** 9:45 AM - 11:00 AM

**Location:** E354b

**The Formula for Success:** Targeting CD30 in Hodgkin's Disease

*John Leonard, MD*
• TDM-1: Hitching a Ride on a Therapeutic Antibody  
  Howard A. Burris, MD (Chair)
• Credentialing Novel Antigens for Targeting with Antibody-Drug Conjugates  
  James D. Marks, MD, PhD

**Session Title:** Endpoints for Cancer Trials in 2012: Statistical, Regulatory, and Clinical Perspectives (eQ&A)  
**Session Type:** Education Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E353
• A Biostatistician’s Perspective on Endpoint Selection  
  Daniel J. Sargent, PhD (Chair)
• A Regulatory Perspective on Clinical Trial Endpoints  
  Ann T. Farrell, MD
• Capturing the Patient Perspective: Patient-Reported Outcomes as Endpoints  
  Deborah Bruner, PhD, RN

**Session Title:** Genomics in Gynecologic Cancers: Important Findings from the Cancer Genome Atlas and Beyond  
**Session Type:** Education Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** S406
• Genomics in Endometrial Cancer  
  Paul J Goodfellow, PhD
• The Clinical Implications of Genomics and The Cancer Genome Atlas  
  Douglas A. Levine, MD (Chair)
• Impact of the Cancer Genome Atlas in Ovarian Cancer  
  Paul Spellman, PhD

**Session Title:** Key Questions in the Loco-regional Treatment of Breast Cancer  
**Session Type:** Education Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E Hall D1
• Surgery for Early-Stage Breast Cancer: How Much Is Too Much?  
  Monica Morrow, MD
• How Does Biology Impact Local Therapy Decisions?  
  Thomas A. Buchholz, MD
• Nagging Questions in Radiation Therapy: Alternatives to Classic Whole-Breast Radiation and Postmastectomy Radiation  
  Richard C. Zellars, MD (Chair)

**Session Title:** Current State of the Art in Managing Gastrointestinal Stromal Tumor - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E451b
• State of the Art and Controversies in Managing GIST: What To Do  
  Margaret von Mehren, MD

**Session Title:** Management of Relapsed Refractory Myeloma - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 9:45 AM - 11:00 AM  
**Location:** E451a
• How To Treat Relapsed Myeloma  
  Kenneth Carl Anderson, MD

**Session Title:** Genetics, the Environment, and Cancer Risk: The Case for Melanoma, Colon, and Lung Cancer
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** S100bc  
- Gene-Environment Interactions in Melanoma  
  *Sancy Ann Leachman, MD (Chair)*  
- The Role of Vitamin D in Colon Cancer  
  *Martha L. Slattery, PhD*  
- Lung Cancer Genetics and Environmental Exposure Risks  
  *Margaret R. Spitz, MD*

**Session Title:** Glioblastoma: Taking the Standard of Care to the Cutting Edge  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** S406  
- Review of the Essentials of Glioblastoma Multiforme Biology as It Pertains to Practical Therapeutics  
  *Daniel Brat, MD, PhD*  
- What Constitutes Standard of Care of Newly Diagnosed and Recurrent Glioblastoma Multiforme?  
  *Mark R. Gilbert, MD (Chair)*  
- Beyond Radiation, Temozolomide, and Bevacizumab: Future Directions in Glioblastoma Multiforme Therapeutics  
  *Howard Colman, MD, PhD*

**Session Title:** Lung Cancer Screening 101  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E Hall D2  
- The National Lung Screening Trial Results  
  *Christine D. Berg, MD (Chair)*  
- CT Screening: Operational Aspects and Opportunities  
  *Denise R. Aberle, MD*  
- The Management of Pulmonary Nodules: An Algorithm-Based Approach  
  *Douglas E. Wood, MD*

**Session Title:** New Diagnostics and Devices in the Era of Comparative Effectiveness  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** S100a  
- Genomic Testing: Are We Improving Patient Outcomes?  
  *Muin Khoury, MD, PhD*  
- Genomic Testing in Oncology: Raising the Bar for Uptake in Clinical Practice  
  *Daniel F. Hayes, MD (Chair)*  
- New Technologies in Cancer Care  
  *David Ransohoff, MD*

**Session Title:** Possible Impact of the Proposed Changes to the Common Rule on Clinical Trial Practice (eQ&A)  
**Session Type:** Education Session  
**Time:** 11:30 AM - 12:45 PM  
**Location:** E353  
  *Jerry Menikoff, MD, JD (Chair)*
• The Revised Common Rule: Institutional Review Board and Data and Safety Monitoring Board Logistics
  
  Donald A. Berry, PhD

• Biospecimens and the Revised Common Rule
  
  Carolyn C. Compton, MD, PhD

**Session Title:** Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next (eQ&A)

**Session Type:** Education Session

**Time:** 11:30 AM - 12:45 PM

**Location:** E Hall D1

• How We Got To What We Do for Adjuvant Therapy for Stage III Disease?
  
  Thierry Andre (Chair)

• What Went Wrong in Adjuvant Therapy? Lack of Efficacy of Drugs That Work in Metastatic Disease?
  
  Bert H. O’Neil, MD

• Where Do We Go From Here?
  
  Jeffrey A. Meyerhardt, MD, MPH

**Session Title:** The ASCO Quality Oncology Practice Initiative and Beyond

**Session Type:** Education Session

**Time:** 11:30 AM - 12:45 PM

**Location:** S404

• Why Measure Quality in Oncology? How Do We Do It? How Does QOPI Fit into This Process? Does It Really Matter?
  
  Joseph O. Jacobson, MD (Chair)

• A QOPI Primer: What Does the Member Considering Participation Need to Know?
  
  Michael N. Neuss, MD

• Developing a Rapid Learning System in Cancer Care
  
  Robert Hauser, PhD, PharmD

**Session Title:** The Many Options for Breast Imaging: What to Use When

**Session Type:** Education Session

**Time:** 11:30 AM - 12:45 PM

**Location:** N Hall B1

• Breast Cancer Screening for Everyone: What Do We Do and What Are the Nuances?
  
  Karla Kerlikowske, MD

• Integration of Advanced Imaging into Breast Cancer Diagnosis
  
  Maxine S. Jochelson, MD

• Breast Cancer "Screening" for Breast Cancer Survivors
  
  Chris Flowers, MD (Chair)

**Session Title:** A Multidisciplinary Approach to Integrating Local Therapies with Systemic Approach in Soft Tissue Sarcomas - Ticketed Session

**Session Type:** Meet the Professor Session

**Time:** 11:30 AM - 12:45 PM

**Location:** E451b

• Meet the Professor: Multidisciplinary Care in Sarcomas of Soft Tissues
  
  Raphael E. Pollock, MD, PhD

• Meet the Professor: Multidisciplinary Care in Sarcomas of Soft Tissues
  
  Laurence H. Baker, DO

**Session Title:** Immune-Related Adverse Events (IrAEs) of CTLA-4 Blockade: Patient Selection, Recognition, and Management of IrAEs - Ticketed Session

**Session Type:** Meet the Professor Session
**Session Title:** Immunotherapy for Myeloma  
**Session Type:** Clinical Science Symposium  
**Time:** 11:30 AM - 1:00 PM  
**Location:** E354b

- **Chair**
  Andrzej J. Jakubowiak, MD, PhD

- Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma. (Abstract #8018)
  Robert Z. Orlowski

- Daratumumab, a CD38 mab, for the treatment of relapsed/refractory multiple myeloma patients: Preliminary efficacy data from a multicenter phase I/II study. (Abstract #8019)
  Torben Plesner

- A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. (Abstract #8020)
  Philippe Moreau

- **Discussion**
  Andrzej J. Jakubowiak, MD, PhD

---

**Session Title:** New Discoveries and Treatments for Central Nervous System Tumors  
**Session Type:** Clinical Science Symposium  
**Time:** 11:30 AM - 1:00 PM  
**Location:** S504

- **Co-Chair**
  Nicholas K. Foreman, MD

- **Co-Chair**
  Maryam Fouladi, MD

- Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma. (Abstract #9518)
  Giles W. Robinson

- **Discussion**
  Ching C. Lau, MD, PhD

- A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. (Abstract #9519)
  Birgit Geoerger

- **Discussion**
  Amar J. Gajjar, MD

- Real-time dynamic and sequential tracking of tumor propagation and associated immune responses in the CNS microenvironment. (Abstract #9520)
  Alex Yee-Chen Huang

- **Discussion**
  Nicholas K. Foreman, MD

---

**Session Title:** Targeting Therapeutics for Thyroid Cancers  
**Session Type:** Clinical Science Symposium  
**Time:** 11:30 AM - 1:00 PM  
**Location:** E354a
Chair

Cherie-Ann Nathan, MD

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (Abstract #5508)

Patrick Schoffski

Discussion

Samuel A. Wells, MD

Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib. (Abstract #5509^)

Alan Loh Ho

Discussion

Marcia S. Brose, MD, PhD

A molecular diagnostic panel for thyroid cancer disease management. (Abstract #5510)

Shih-Min Cheng

Discussion

Yuri Nikiforov, MD, PhD

Session Title: ASCO/Society of Nuclear Medicine (SNM) Joint Session: PET Criteria for Response Assessment and Timing of the Scans

Session Type: Special Session

Time: 1:15 PM - 2:30 PM

Location: E354a

- Nuts and Bolts of Assessing Response byPET
  Homer A. Macapinlac, MD

- How DifferentPET Response Criteria Compare to Each Other in the Clinical Setting
  Erik Mittra, MD, PhD

- Novel PET Tracers and Their Future Use in Assessment of Response to Treatment
  Andrei Iagaru, MD (Co-Chair)

Closing Remarks

Michael Paul Link, MD (Co-Chair)

Session Title: Global Variations in Access to New Therapies for Sarcomas and Gastrointestinal Stromal Tumor

Session Type: Education Session

Time: 1:15 PM - 2:30 PM

Location: S406

- What Metrics to Use to Define Clinical Benefit in Sarcomas? Do We Agree Internationally?
  George D. Demetri, MD (Chair)

- Decision Making in Patients with Sarcoma Following Failure of Conventional Therapies: Off Label or Hospice?
  Stefan Sleijfer, MD, PhD

- The Role of Physicians in Advocating for Patients when Cost-effectiveness Is Raised by Administrative Bodies Such as NICE
  Ian Robert Judson, MD

Session Title: How to Manage Very Rare Pediatric Cancers

Session Type: Education Session

Time: 1:15 PM - 2:30 PM

Location: S504

- Treating Rare Cancer in Children: The Importance of Evidence?
  Alberto S. Pappo, MD (Chair)
• Melanoma in Children
  Fariba Navid, MD
• Desmoid-Type Fibromatosis: A Step Forward in the Cooperative Group Setting
  Stephen Skapek, MD

Session Title: Overcoming Disparities in Clinical Trial Accrual among African Americans
Session Type: Education Session
Time: 1:15 PM - 2:30 PM
Location: S100bc

• Introduction
  Sandra M. Swain, MD (Chair)

• What Factors Influence African American Cancer Patients’ Decisions Regarding Participation in Clinical Trials?
  Jean Ford, MD

• Use of Culturally Targeted Video for Changing Attitudes Toward Clinical Trials
  Deliya Banda, PhD, MPH

• A Critical Review of Clinical Trial Enrollment of African Americans in Clinical Trials
  Worta J. McCaskill-Stevens, MD

Session Title: Perspectives on Headline-Making News in Neuro-oncology
Session Type: Education Session
Time: 1:15 PM - 2:30 PM
Location: S404

• Antiangiogenesis Therapies: When Should It Be Used and Is More Better?
  Timothy Francis Cloughesy, MD (Chair)

• Immunologic Therapies: What’s Hot and Which Approach Is Best for my Patient?
  E. Antonio Chiocca, MD, PhD

• Changing the Electrical Field around the Tumor Cell: How Does It Work and How Should We Use It?
  Philip H. Gutin, MD

Session Title: Recent Clinical Highlights in Gynecologic Oncology
Session Type: Education Session
Time: 1:15 PM - 2:30 PM
Location: E Arie Crown Theater

• The International Perspective on Global Advances in Gynecologic Oncology
  Lynette Denny, MD, PhD (Chair)

• Updates from the Annual Meeting of the Society of Gynecologic Oncology
  D. Scott McMeekin, MD

• The European Society of Gynecologic Oncology Update
  Nicoletta Colombo, MD

Session Title: Recent Innovations in the Management of Genitourinary Cancers (eQ&A)
Session Type: Education Session
Time: 1:15 PM - 2:30 PM
Location: E Hall D1

• New Developments in Renal Cancer
  Robert John Motzer, MD

• New Developments in Prostate Cancer
  Elisabeth I. Heath, MD

• New Developments in Urothelial Cancer
  Matt D. Galsky, MD (Chair)
**Session Title:** Talking in Sync with Patients across Cultural Barriers  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** S100a  
- New Insights in Cross Cultural Communication  
  *Lidia Schapira, MD (Chair)*  
- Communication, Decision Making, and Cancer: What African Americans Want Physicians to Know  
  *William J. Hicks, MD*  
- Communicating with Latino Patients and Their Families  
  *Louise Villejo, MPH*

**Session Title:** Targeting Critical Molecular Aberrations Early in the Course of Solid Tumors: Is It about Time?  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E354b  
- Lessons From CML: How Applying Targeted Therapy to Newly Diagnosed Disease Transformed Outcomes  
  *Hagop Kantarjian, MD*  
- Rationale for Applying Targeted Therapies Early in Disease Course in Solid Tumors  
  *Razelle Kurzrock, MD (Chair)*  
- Novel Trial Design and Path to Approval for Targeted Therapy in Early-Stage Solid Tumors  
  *Laura Esserman, MD, MBA*

**Session Title:** Update of the Oxford Overview: New Insights and Perspectives in the Era of Personalized Medicine  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** N Hall B1  
- What Are the Gaps from Genomics and When Is the Overview Still Relevant?  
  *Kathleen I. Pritchard, MD*  
- Presentation of Updated Overview Data  
  *Carl Bergh, MD*  
- What Have We Learned from the Use of Genomics and How Has That Advanced Our Treatment Decisions?  
  *Harold J. Burstein, MD, PhD (Chair)*

**Session Title:** Using Social Media in Oncology for Education and Patient Engagement (eQ&A)  
**Session Type:** Education Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E353  
- Overview of Social Media Tools, Risks, and Benefits  
  *Michael A. Thompson, MD, PhD*  
- Use of Social Media for Patient Engagement and Clinical Trial Recruitment  
  *Anas Younes, MD (Chair)*  
- Social Media for Professional Education  
  *Robert Stephen Miller, MD*

**Session Title:** Bringing Personalized Cancer Therapy into Routine Use - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E451b  
- Personalized Cancer Therapy  
  *John Mendelsohn, MD*
**Session Title:** Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma: Beyond Surgery - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 1:15 PM - 2:30 PM  
**Location:** E451a

- Cutaneous SCC and BCC Management  
  Caroline Robert, MD, PhD

---

**Session Title:** Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy  
**Session Type:** Poster Discussion Session  
**Display Time:** 1:15 PM - 5:15 PM  
**Display Location:** E450b  
**Discussion Time:** 4:45 PM - 5:45 PM  
**Discussion Location:** N Hall B1

- Co-Chair  
  Nancy U. Lin, MD  
- Co-Chair  
  George Somlo, MD

Brd. 1
- Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. (Abstract #1009)  
  Judith Balmaña

Brd. 2
- ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial. (Abstract #1010)  
  George Somlo

Brd. 3
- SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). (Abstract #1011)  
  Antonio Llombart

Brd. 4
- DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. (Abstract #1012)  
  Libero Santarpia

Brd. 5
- HAGE (DDX43) protein expression as an independent biomarker of poor clinical outcome of breast cancer (BC) and potential as a therapeutic target for ER-negative BC. (Abstract #1013)  
  Stephen Chan

Brd. 6
- Targeting XRCC1 (X-ray repair cross-complementing gene 1) deficiency in tumors for personalized cancer therapy. (Abstract #1014)  
  Srinivasan Madhusudan

- Discussion  
  Nicholas C. Turner, PhD, MRCP

Brd. 7
- Cancer gene profile of metastatic breast cancer. (Abstract #1015)  
  Funda Meric-Bernstam

Brd. 8
- Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer. (Abstract #1016)  
  Andrew David Seidman
Brd. 9
• Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC). (Abstract #1017)
  *Cynthia R. C. Osborne*

Brd. 10
• Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI). (Abstract #1018)
  *Denise Aysel Yardley*

Brd. 11
• Metformin in early breast cancer (BC): A prospective, open-label, neoadjuvant “window of opportunity” study. (Abstract #1019)
  *Saroj Niraula*

Brd. 12
• The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC). (Abstract #1020)
  *Christof Vulsteke*

• Discussion
  *Stacy L. Moulder, MD*

Brd. 13
• 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features. (Abstract #1021)
  *Joseph A. Sparano*

Brd. 14
• Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. (Abstract #1022)
  *Giuseppe Viale*

Brd. 15
• Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. (Abstract #1023)
  *Gunter Von Minckwitz*

Brd. 16
• A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer. (Abstract #1024)
  *Justin M. Balko*

Brd. 17
• NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC). (Abstract #1025)
  *Antoinette R. Tan*

Brd. 18
• A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). (Abstract #1026)
  *Sara M. Tolaney*
Brd. 19
- Association of a compact 13-gene VEGF signature with OS in E2100. (Abstract #1027)
  
  scooter willis

- Discussion
  
  hope s. rugo, md

Brd. 20
- Are mastectomy rates really increasing? Experiences from a single institution and a population-based database. (Abstract #1028)
  
  min yi

Brd. 21
- Breast cancer multifocality-multicentricity and locoregional recurrence. (Abstract #1029)
  
  xiudong lei

Brd. 22
- Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009. (Abstract #1030)
  
  Carolyn J. presley

Brd. 23
  
  Jennifer Nishimura

Brd. 24
- Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer. (Abstract #1032)
  
  shaheenah S. Dawood

Brd. 25
- Utilization of post-lumpectomy radiation therapy in women 70 years of age or older: A report from the National Cancer Data Base. (Abstract #1033)
  
  katharine Yao

- Discussion
  
  Reshma Jagsi, MD, DPhil

---

**Session Title:** Gastrointestinal (Noncolorectal) Cancer

**Session Type:** Poster Discussion Session

**Display Time:** 1:15 PM - 5:15 PM

**Display Location:** E450a

**Discussion Time:** 4:45 PM - 5:45 PM

**Discussion Location:** E Hall D1

- Co-Chair
  
  Michael J. Overman, MD

- Co-Chair
  
  Eunice Lee Kwak, MD, PhD

Brd. 1
- Adverse prognostic impact of heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma (EAC). (Abstract #4009)
  
  Harry H. Yoon

Brd. 2
- Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. (Abstract #4010)
  
  Michael Alexander Gordon
• Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis. (Abstract #4011)
  
  Phillip Sangwook Kim

• Impact of insulin-like growth factor 1 receptor (IGF1R) and amphiregulin (AREG) expressions on survival in patients with stage II/III gastric cancer enrolled in the ACTS-GC study. (Abstract #4012)
  
  Wataru Ichikawa

• Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis. (Abstract #4013)
  
  Daniel D. Von Hoff

• Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). (Abstract #4014)
  
  James C. Yao

• Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. (Abstract #4015)
  
  Halfdan Sorbye

• Discussion
  
  Andrea Wang-Gillam, MD, PhD

• Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603). (Abstract #4017)
  
  Michele Reni

• FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGE0 phase II trial FIRGEM. (Abstract #4018)
  
  Isabelle Trouilloud

• Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727). (Abstract #4019)
  
  Philip Agop Philip

• Long-term survival in patients with pancreatic cancer: Relevant factors in CONKO-001. (Abstract #4020)
  
  Marianne Sinn

• Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. (Abstract #4021)
  
  Theodore S. Hong
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. (Abstract #4022)

Daniel Virgil Thomas Catenacci

Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC. (Abstract #4023)

Michael Haas

Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer. (Abstract #4026)

Takeru Wakatsuki

Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA). (Abstract #4027)

Peter C. Enzinger

A randomized phase II study of continuous versus intermittent S-1 plus oxaliplatin in first-line treatment of patients with metastatic gastric carcinoma. (Abstract #4028)

Sook Ryun Park

The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial. (Abstract #4029)

David Sebag-Montefiore

Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. (Abstract #4030)

Madhur Garg

Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population. (Abstract #4033)

Joong-Won Park
Discussion

Jennifer J. Knox, MD

**Session Title:** Patient and Survivor Care

**Session Type:** Poster Discussion Session

**Display Time:** 1:15 PM - 5:15 PM

**Display Location:** S102

**Discussion Time:** 4:45 PM - 5:45 PM

**Discussion Location:** S100a

- Co-Chair
  
  Karen Michelle Mustian, PhD, MPH

- Co-Chair
  
  Debra L. Barton, PhD, AOCN, RN

Brd. 1

- A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). (Abstract #9017)
  
  Yuanjue Sun

Brd. 2

- SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. (Abstract #9018)
  
  Dawn L. Hershman

Brd. 3

- Low-level laser therapy for chemotherapy-induced peripheral neuropathy. (Abstract #9019)
  
  John Muzi Lee

Brd. 4

- Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx). (Abstract #9020)
  
  Lynne I. Wagner

Brd. 5

- Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study. (Abstract #9021)
  
  Janette L. Vardy

Brd. 6

- Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial. (Abstract #9022)
  
  Kelly-Anne Phillips

- Discussion
  
  Debra L. Barton, PhD, AOCN, RN

Brd. 7

- Methylphenidate (MP) and nursing telephone intervention (NTI) for cancer-related fatigue (CRF) in advanced cancer patients: A double-blind randomized phase II trial. (Abstract #9023)
  
  Eduardo Bruera

Brd. 8

- Phase Ib, multicenter, single blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT). (Abstract #9024)
  
  Sewanti Atul Limaye
• Parenteral hydration (PH) in advanced cancer patients: A multi-center, double-blind, placebo-controlled randomized trial. (Abstract #9025)
  Shalini Dalal

• Effect of cancer cachexia on treatment toxicity in metastatic colorectal cancer patients: Results of a prospective multicenter study. (Abstract #9026)
  Maximilien Barret

• Curcumin for radiation dermatitis: A randomized, double-blind, placebo-controlled clinical trial of 30 breast cancer patients. (Abstract #9027)
  Julie L. Ryan

• YOCAS yoga for musculoskeletal symptoms in breast cancer patients receiving aromatase inhibitors: A URCC CCOP randomized, controlled clinical trial. (Abstract #9028)
  Luke Joseph Peppone

• Discussion
  Paul A. Glare, MBBS

• A randomized controlled trial of expressive writing for patients with renal cell carcinoma (RCC). (Abstract #9029)
  Timothy Burnight

• Association of screening for psychosocial distress in patients with newly diagnosed stage IV NSCLC and survival. (Abstract #9030)
  William F. Pirl

• The effect of pretreatment psychosocial factors on immune function and quality of life after brief presurgical stress management. (Abstract #9031)
  Chelsea D. Gilts

• Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors. (Abstract #9032)
  Lawson Eng

• Strength and endurance training in the treatment of lung cancer patients staged IIIA/IIIB/IV. (Abstract #9033)
  Corinna C. Henke

• Discussion
  Camilla Zimmermann, MD, PhD

• Factors associated with life expectancy (LE) < 3 months (mo) among older adults receiving palliative chemotherapy (chemo). (Abstract #9034)
  Arti Hurria

• The influence of age plus standard clinical approach with or without comprehensive geriatric assessment (CGA) on treatment decisions in older cancer patients: Final results. (Abstract #9035)
  Lore Decoster
Patient information desire in actual decision making for advanced cancer treatment: Do doctors know their patients? (Abstract #9036)

Linda JM Oostendorp

Women know, and men wish they knew, prognostic information in advanced cancer. (Abstract #9037)

Kalen M Fletcher

Discussion

Larry Dean Cripe, MD

Session Title: Health Services Research

Session Type: General Poster Session

Time: 1:15 PM - 5:15 PM

Location: S Hall A2

Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs). (Abstract #6038)

Philip Edward Lammers

Do patient-reported symptoms predict for emergency department visits? A population-based analysis. (Abstract #6039)

Lisa Catherine Barbera


Tomasz Czechura

Conflict of interest disclosure in off-label oncology clinical trials. (Abstract #6041)

Blair Billings Irwin

Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastic. (Abstract #6042)

Benyam Muluneh

Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC). (Abstract #6043)

Francisco Emilio Vera Badillo

Unintended consequences of health information technology: Evidence from Veterans Affairs Colorectal Cancer Oncology Watch Intervention. (Abstract #6044)

John Bian

Osteoporosis screening among prostate cancer survivors treated with androgen deprivation therapy. (Abstract #6045)

Alicia Katherine Morgans

Association of increases in quality of care with the NCI Community Cancer Center Program (NCCCP) pilot. (Abstract #6046)

Michael T. Halpern
• Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrials.gov. (Abstract #6047)
  
  Steven Kunyuan Cheng

• Electronic prompt to improve outpatient code status documentation for advanced lung cancer. (Abstract #6048)
  
  Jennifer S. Temel

• Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study. (Abstract #6049)
  
  John J. You

• How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California? (Abstract #6050)
  
  Manali I. Patel

• Improving the impact of clinical research: A systematic analysis of kidney cancer trials. (Abstract #6051)
  
  Bradford Richard Hirsch

• Influence of comorbidity on guideline concordant care for breast cancer: Findings from the Center for Disease Control and Prevention National Program of Cancer Registry (NPCR) patterns of care study. (Abstract #6052)
  
  Gretchen Genevieve Kimmick

• Examining patient choices for metastatic breast cancer drugs. (Abstract #6053)
  
  Mary Lou Smith

• A brief educational intervention to increase communication about complementary and alternative medicine (CAM) in community oncology settings. (Abstract #6054)
  
  Lorenzo Cohen

• Self-reported conflicts of interest (sfCOI) of authors and the interpretation of randomized phase III trials (RCT) and related editorials (REd) in cancer research. (Abstract #6055)
  
  Giovanni Mendonca Bariani

• The cost-effectiveness of improving cancer screening compliance. (Abstract #6057)
  
  Michael S. Broder

• Treatment and treatment outcomes of advanced NSCLC patients in routine clinical care: Results of the retrospective LUCEOR study. (Abstract #6058)
  
  Jason Scott Agulnik

• Health care costs associated with venous thromboembolism in select high-risk ambulatory solid tumor patients in the United States. (Abstract #6059)
  
  Alok A. Khorana
• Use and spending on antineoplastic therapy (AT) in the Medicare population and the role of supplemental coverage. (Abstract #6060)
  Amy J. Davidoff

• Disparities in preoperative imaging for breast cancer: Not so black and white. (Abstract #6061)
  Richard J. Bleicher

• Patient-related predictors of poor quality pain care in advanced lung cancer patients. (Abstract #6062)
  Inga Tolin Lennes

• Rural versus urban differences among patients (pts) with hormone-receptor positive (HR+) breast cancer (BC) and a 21-gene assay recurrence score (RS). (Abstract #6063)
  Molly Andreason

• Impact of county-level surgical specialist density on breast (BrCa) and lung cancer (LuCa) mortality. (Abstract #6064)
  Andrei Karpov

• Prevalence and characteristics of patients with stage IV solid tumors who receive no anticancer therapy. (Abstract #6065)
  Alexander C. Small

• Utility of positron emission tomography (PET) scans on the management of cancers of unknown primary. (Abstract #6066)
  Hao Chen

• The use of the word “cure” in oncology. (Abstract #6067)
  Kenneth David Miller

• Sown the seeds: An analysis of published trials in clinical oncology. (Abstract #6068)
  Natalie M. Spradlin

• Effectiveness of a screening intervention to identify clinical-trial eligible patients. (Abstract #6069)
  Leo Chen

• Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas. (Abstract #6070)
  Gita Suneja

• Burnout prevalence in medical and radiation oncologists at British Columbia Cancer Agency (BCCA). (Abstract #6071)
  Catherine A. Fitzgerald

• Clinical and cost impact of diagnostic slide review. (Abstract #6072)
  Justin Cuff
Colorectal cancer survivors' needs and preferences for survivorship information. (Abstract #6073)

_Talya Salz_

Speed of accrual into published phase III oncology trials: A comparison across geographic locations. (Abstract #6074)

_Nancy R. Ruther_

Out-of-pocket (OOP) health care expenditure burden for Medicare beneficiaries with cancer. (Abstract #6075)

_Ilene H. Zuckerman_

Racial disparities in depressive symptom prevalence and selective serotonin reuptake inhibitor (SSRI) utilization in cancer patients: An analysis from ECOG E2Z02: Symptom Outcomes and Practice Patterns (SOAPP). (Abstract #6076)

_Fengmin Zhao_

Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer. (Abstract #6077)

_Kristin Berry_

Deviations from guideline-based therapy for febrile neutropenia in cancer patients. (Abstract #6078)

_Jason D. Wright_

Surveillance after potentially curative breast cancer treatment: The impact of HMOs. (Abstract #6079)

_Robert J. Avino_

The relationship between symptom burden and perceived comorbidity in outpatients with common solid tumors. (Abstract #6080)

_Christine Ritchie_

Physician age and surveillance intensity following curative-intent treatment for breast cancer patients. (Abstract #6081)

_Steven F. Abboud_

Comparison of drug approval between health Canada (HC) and the U.S. Food and Drug Administration (FDA). (Abstract #6082)

_Doreen Anuli Ezeife_

Chemotherapy in the oldest old: The feasibility of cytotoxic therapy in the 80+ population. (Abstract #6083)

_Shelly Sud_

Does drug cost drive drug adherence? The designer drug phenomenon. (Abstract #6084)

_Jalal Ebrahim_
• Physical activity (PA) and physical function (PF) in adult cancer survivors (CS). (Abstract #6085)
  
  Peter Crawford Birks

• The NCI Community Cancer Centers Program (NCCCP): A model for reducing cancer health care disparities. (Abstract #6086)
  
  Donna M. O’Brien

• Involvement of low- and middle-income countries (LMCs) in oncology randomized controlled trials (RCTs). (Abstract #6087)
  
  Janice C. Wong

• Beyond the performance rate: Understanding differences in treatment status using the Rapid Quality Reporting System (RQRS). (Abstract #6088)
  
  Erica J. McNamara

• Use and duration of chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy (tx). (Abstract #6089)
  
  Davinia Shien Seah

• Health-related quality of life assessment in EORTC cancer clinical trials. (Abstract #6090)
  
  Efstathios Zikos

• Five-fold increase in recruitment of cancer patients to National Institute for Health research cancer research network portfolio studies between 2001 and 2011. (Abstract #6091)
  
  Matthew Cooper

• Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #6092)
  
  David Cella

• Unanticipated hospital admissions in patients undergoing radiotherapy with or without concurrent chemotherapy: Incidence and predictive factors. (Abstract #6093)
  
  Nabeel H. Arastu

• Association between financial relationships with commercial interests and research merit at the ASCO Annual Meeting (AM). (Abstract #6095)
  
  Beverly Moy

• Cost-effectiveness of adjuvant radiotherapy for older women with early hormone-receptor positive breast cancer. (Abstract #6096)
  
  Katherine Elizabeth Reeder-Hayes

• The impact of race/ethnicity concordance between patients and their navigators in time to diagnostic resolution of breast and cervical cancer screening abnormalities. (Abstract #6097)
  
  Marjory Charlot

• Relationship between Oncotype DX testing and the use of chemotherapy in high-risk patients (pts). (Abstract #6098)
  
  Winston Wong
Utilization of bone densitometry and administration of bisphosphonates to prevent osteoporosis in patients with nonmetastatic prostate cancer receiving anti-androgen therapy. (Abstract #6099)

Muhammad Atif Khan

Quality of life of elderly patients undergoing concomitant chemoradiation therapy for head and neck cancers, including assessment of geriatric parameters. (Abstract #6100)

Martine Extermann

Long-term central venous catheter use among cancer patients in administrative claims data. (Abstract #6101)

Allison Nicole Lipitz Snyderman

Assessment of cancer registries (CR) in low- and middle-income countries (LMCs). (Abstract #6102)

Leah L. Zullig

Development of a disease-specific measure of quality of life in myelodysplastic syndromes (MDS): The “QUALMS-1”. (Abstract #6103)

Gregory Alan Abel

Differential receipt of sentinel lymph node biopsy within practice-based research networks. (Abstract #6104)

Anne-Marie Meyer

Comparative effectiveness of erlotinib versus no treatment for advanced non-small cell lung cancer patients in the Veterans Administration. (Abstract #6105)

Benjamin Kim

Advanced gastrointestinal cancer patients' perceptions of prognosis and goals of treatment. (Abstract #6106)

Areej El-Jawahri

Association between baseline physical function and comorbidity status with patient-reported quality of life after prostate cancer treatments: Combined analysis of two prospective cohort studies. (Abstract #6107)

Ronald C. Chen

Assessing the clinical significance of real-time quality of life data in cancer patients treated with radiation therapy. (Abstract #6108)

Michele Y. Halyard

Changes in adjuvant breast cancer chemotherapy regimen selection over time in the community. (Abstract #6109)

Debra A. Patt

Frequency of cognitive impairment (CI) in elderly patients (pts) suffering from malignancies and impact on therapeutic decision. (Abstract #6110)

Thibault De La Motte Rouge
Br. 10D
• Cancer survivorship outcomes in immigrants. (Abstract #6111)
  
  Phyllis Noemi Butow

Br. 10E
• An integrated analysis of comprehensive geriatric assessment (CGA) in elderly patients with non-small cell lung cancer (NSCLC) (JCOG1115-A). (Abstract #6112)
  
  Hiroshi Katayama

Br. 10F
• Implications of smoking for quality of life and illness perceptions of lung cancer patients. (Abstract #6113)
  
  Sarah Danson

Br. 10G
• Impact of oncology drug shortages on patient treatment. (Abstract #6114)
  
  Daniel Jacob Becker

Br. 10H
• Participation of teenagers and young adults (TYA) in cancer clinical trials (CCT): What can we learn from six years of accrual data in England? (Abstract #6115)
  
  Lorna Anne Fern

Br. 11A
• Pregnancy outcomes in women with cancer. (Abstract #6116)
  
  Andrea Milbourne

Br. 11B
• Financial burdens (FB), quality of life, and psychological distress among advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC). (Abstract #6117)
  
  Fay J. Hlubocky

Br. 11C
• Influence of hospital characteristics on immediate breast reconstruction following mastectomy. (Abstract #6118)
  
  Catherine A. Richards

Br. 11D
• Why do cancer patients die in the emergency department (ED)? Analysis of 283 deaths in North Carolina EDs in 2008. (Abstract #6119)
  
  Ashley Nicole Leak

Br. 11E
• Do patient tracking, follow-up, and referral practices contribute to breast cancer disparities in a large urban area? (Abstract #6120)
  
  Christine B. Weldon

Br. 11F
• Competing event risk stratification may improve the design and efficiency of clinical trials: Secondary analysis of SWOG 8794. (Abstract #6121)
  
  Brent Shane Rose

Br. 11G
• Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL). (Abstract #6122)
  
  Christopher Flowers

Br. 12A
• Loss to follow-up of cancer patients in the poorest district of the United States. (Abstract #6123)
  
  Antranik Mangardich
• Prevalence and predictors of adherence to antiemesis prophylaxis in lung cancer: A population-based study. (Abstract #6124)
  Daniel Richard Gomez

• In-hospital mortality of patients admitted through the emergency department of a comprehensive cancer center. (Abstract #6125)
  Ahmed F. Elsayem

• Caring for Alaska native prostate cancer survivors in primary care: A survey of Alaska Tribal Health System providers. (Abstract #6126)
  Jon C. Tilburt

• Geographic and socioeconomic determinants of participation by elderly patients in surgical oncology trials. (Abstract #6127)
  John H. Stewart

• Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting. (Abstract #6128)
  Angela R. Bradbury

• Chemotherapy associated myelosuppression and disease-free and overall survival: A systematic review and evidence summary. (Abstract #6129)
  Marek S. Poniewierski

• Multidisciplinary assessment and reporting of fitness to drive in brain tumor patients: A gray matter. (Abstract #6130)
  Alexander V. Louie

• Sociodemographic and patient disparities in use of first-line chemotherapy (CT) in older adult patients (pts) with advanced non-small cell lung cancer (AdvNSCLC): Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare data. (Abstract #6131)
  Josephine Louella Feliciano

• Predictors of retention in a cervical cancer survivorship study. (Abstract #6132)
  Lari B. Wenzel

• Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392). (Abstract #6133)
  Cynthia Chauhan

• Relationship of MRI tests and referral of malignant adnexal masses to gynecologic oncologists for surgery. (Abstract #6134)
  Rachel Kupets

• Patient-reported toxicity after treatment for cancers of the head and neck. (Abstract #6135)
  Christine E. Hill-Kayser
• Relationship between whole-body tumor burden and quality of life in patients with neurofibromatosis. (Abstract #6136)
  
  Scott Randall Plotkin

Brd. 13G
• Predictive factors on the receipt and completion of adjuvant chemotherapy in a mixed sociodemographic cohort of patients. (Abstract #6137)
  
  Blase N. Polite

---

**Session Title:** Leukemia, Myelodysplasia, and Transplantation

**Session Type:** General Poster Session

**Time:** 1:15 PM - 5:15 PM

**Location:** S Hall A2

Brd. 14A
• Impact of treatment prior to allogeneic stem cell transplantation for myelodysplastic syndromes: A study on behalf of the SFGM-TC and the GFM groups. (Abstract #6534)
  
  Gandhi Laurent Damaj

Brd. 14B
• Immune-reconstitution after combined haploidentical and umbilical cord blood transplantation. (Abstract #6535^)
  
  Koen van Besien

Brd. 14C
• Impact of ATG on new HLA groups for unrelated donor allogeneic stem cell transplantation. (Abstract #6536)
  
  Soo Jung Lee

Brd. 14D
• Low day 100 transplant-related mortality (TRM) and relapse rate following clofarabine (CLO) in combination with cytarabine, total body irradiation (TBI), and allogeneic stem cell transplantation (AlloSCT) in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. (Abstract #6537)
  
  Kavita Radhakrishnan

Brd. 14E
• The outcomes of allogeneic stem cell transplantation in AML patients with monosomal karyotypes. (Abstract #6538)
  
  Sang Kyun Sohn

Brd. 14F
• Effect of IL-22 on intestinal stem cells, GVHD-related tissue damage, and GVL. (Abstract #6539)
  
  Alan M. Hanash

Brd. 14G
• Outcomes of second allogeneic hematopoietic stem cell transplantation (SCT) for patients with acute lymphoblastic leukemia (ALL). (Abstract #6540)
  
  LM Poon

Brd. 14H
• Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-TK donor lymphocytes in patients with high-risk acute leukemia. (Abstract #6541)
  
  Claudio Bordignon
Impact of antithymocyte globulin (ATG)-containing conditioning regimens on patients undergoing allogeneic stem cell transplantation (allo-CST) for poor risk cytogenetic IPSS myelodysplastic syndrome (PRC-MDS): A report from the French Society of Stem Cell Transplantation and Cell Therapy (SFGM-TC). (Abstract #6542)

Ibrahim Yakoub-Agha

Minimum tolerable interval of 90 yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. (Abstract #6543)

Justin Hasenkamp

Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. (Abstract #6544)

Naval Guastad Daver

A phase II trial 90y-ibritumomab tiuxetan in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma. (Abstract #6545)

Auayporn Nademanee

Neurotoxicity after high-dose melphalan. (Abstract #6546)

Jose Eugenio Najera

Effect of radioimmunotherapy-based conditioning for autologous stem cell transplantation on poor risk molecular profiling in diffuse large B-cell lymphoma. (Abstract #6547)

Tanya Siddiqi

Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL). (Abstract #6548)

Jan-Willem Henning

Effect of lenalidomide induction therapy on peripheral blood stem cell collection in patients undergoing autologous stem cell transplant for multiple myeloma. (Abstract #6549)

Divaya Bhutani

The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin’s lymphomas: Results of a retrospective analysis. (Abstract #6550)

Mustafa Ozturk

Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. (Abstract #6551)

Nina Shah

Secondary neutropenia (SN) after autologous hematopoietic stem cell transplantation (AHSCT) in patients (pts) with lymphoma. (Abstract #6552)

Sunita Nathan
• Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL). (Abstract #6553)
  Wayne Su

• An anthropometric study in children with chronic myeloid leukemia on imatinib. (Abstract #6554)
  Vamshi Krishna Reddy Goteke

• Prevalence of autoimmune manifestations in patients with large granular lymphocytic leukemia: Exploratory analysis of a series of consecutive patients. (Abstract #6555)
  Bruno Bockorny

• Maintenance therapy with arsenic after induction in an alternative and long-term case for the prevention of recurrence of acute promyelocytic leukemia during the period between November 2005 and December 2011. (Abstract #6556)
  Mozaffar Aznab

• Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells. (Abstract #6557)
  Hakan Mellstedt

• Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. (Abstract #6558)
  Mona Lisa Alattar

• Post hoc analysis of relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. (Abstract #6559)
  Chris Arthur

• Increased risk of MDS/AML post radiation treatment for breast cancer: Analysis of SEER data 2001-2008. (Abstract #6560)
  Henry G. Kaplan

• Mevalonate pathway inhibitors in the treatment of B-cell chronic lymphocytic leukemia. (Abstract #6561)
  Ravi Kiran Bobba

• Single center experience treating adults with FLT3-mutated acute myeloid leukemia (AML). (Abstract #6562)
  Anna B. Halpern

• Mitoxantrone and etoposide for acute myeloid leukemia in first relapse. (Abstract #6563)
  Annie P. Im

• Prognostic implication of monosomal karyotype in patients with acute myeloid leukemia who received allogeneic hematopoietic cell transplantation. (Abstract #6564)
  Yunsuk Choi
Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts). (Abstract #6565)

Sagar D Sardesai

Bendamustine retreatment of CLL in the outpatient setting. (Abstract #6566)

Georg Guenther

Effect of epitopes derived from the mutated region of cytoplasmatic nucleophosmine 1 (NPM1) on CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. (Abstract #6567)

Jochen Greiner

Incidence of second and secondary malignancies in patients with CLL: A single institution experience. (Abstract #6568)

Samir Dalia

Induction chemotherapy with high dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients. (Abstract #6569)

Muthalagu Ramanathan

Phase II study of AZD2171 for the treatment of patients with myelodysplastic syndromes. (Abstract #6570)

Shannon Eileen O'Mahar

Overall and cancer-specific survival of breast, colon, and lung cancer in patients with and without chronic lymphocytic leukemia: A SEER population-based study of over 1 million patients. (Abstract #6571)

Benjamin Maurice Solomon

Treatment outcomes in patients older than age 60 with acute myeloid leukemia (AML) in the nonclinical trial setting. (Abstract #6572)

Steven Duffy

A simple but effective model to decrease early deaths in acute promyelocytic leukemia (APL). (Abstract #6573)

Anand P. Jillella

Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma. (Abstract #6574)

Mark Winderlich

Cancer testicular antigens as a prognostic markers of chronic lymphocytic leukemia. (Abstract #6575)

Julio C. Chavez

AML patients with IDH1 or IDH2 mutations treated with hypomethylating agents: A case series. (Abstract #6576)

Christopher Brent Benton
• Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies. (Abstract #6577)
  
  Gail J. Roboz

• Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). (Abstract #6578)
  
  Naveen Pemmaraju

• Outcome of acute myeloid leukemia in patients with a history of autoimmune disease. (Abstract #6579)
  
  Courtney Denton Dinardo

• L-arginine depletion by PEG-arginase I, a new potential therapy for acute lymphoblastic leukemia. (Abstract #6580)
  
  Ofelia Crombet Ramos

• Quantitative detection of ZAP-70 expression in chronic lymphocytic leukemia. (Abstract #6581)
  
  Peixuan Zhu

• Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML). (Abstract #6582)
  
  Nitin Jain

• Real-world response monitoring and tolerability of imatinib treated chronic myeloid leukemia patients captured in a retrospective research registry. (Abstract #6583)
  
  David D. Stenehjem

• Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. (Abstract #6584)
  
  Anders Österborg

• Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias. (Abstract #6585)
  
  Marina Konopleva

• Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML). (Abstract #6586)
  
  Awais M. Khan

• Clinical impact of dose intensity of initial tyrosine kinase inhibitor (TKI) therapy in accelerated phase CML (CML-AP). (Abstract #6587)
  
  Maro Ohanian

• Impact of ABL kinase domain mutations on the outcome of patients with chronic myeloid leukemia (CML). (Abstract #6588)
  
  Kendra Lynn Sweet
A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). (Abstract #6589)

Aziz Nazha

The large granular lymphocytic leukemia registry: A detailed analysis of 79 patients with LGL leukemia and rheumatoid arthritis. (Abstract #6590)

Kirsten Marie Boughan

Pharmacokinetics (PK) and pharmacodynamics (PD) of rituximab administered by faster infusion in patients with previously untreated diffuse large B-cell (DLBCL) or follicular lymphoma (FL). (Abstract #6591)

Michael Brewster

Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6592)

Tapan M. Kadia

Prognostic and predictive significance of smudge cell percentage on routine blood smear in chronic lymphocytic leukemia patients: A single center study from northern India. (Abstract #6593)

Ajay Gogia

Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis. (Abstract #6594)

Lei Chen

Treatment outcome of acute myeloid leukemia (AML) in HIV+ patients. (Abstract #6595)

Irene Ang Dy

Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs). (Abstract #6596)

Luke Paul Akard

FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). (Abstract #6597)

Pavan Kumar Bhamidipati

Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL). (Abstract #6598)

Hun Ju Lee

Expression levels of nucleoside transporter hENT1 and dCK enzyme, as prognostic factors in patients with AML treated with cytarabine. (Abstract #6599)

Carmen Corrales-Alfaro

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia. (Abstract #6600)

Lizheng Shi
• A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts). (Abstract #6601)
  Jeffrey E. Lancet

• A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia. (Abstract #6602)
  Carlos Enrique Vigil

• Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC. (Abstract #6603)
  Francesco Paolo Tambaro

• Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs). (Abstract #6604)
  Meir Wetzler

• Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update. (Abstract #6605)
  Michael J. Mauro

• Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse. (Abstract #6606)
  Amir Tahmasb Fathi

• Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML). (Abstract #6607)
  Michael Mathisen

• Impact of immunoglobulin heavy chain variable region mutational status on the outcome of patients with chronic lymphocytic leukemia harboring isolated 13q deletion. (Abstract #6608)
  Gelenis C. Domingo

• A new paradigm in CLL: Minimizing toxicity by using the minimum effective dose (MED) of lenalidomide for older patients with CLL. (Abstract #6609)
  Nicole Lamanna

• Assessment of age as its own risk factor in AML. (Abstract #6610)
  Thomas Buchner

• Disease response and survival outcomes in acute myeloid leukemia (AML) patients unfit for chemotherapy treated with 10-day decitabine as initial therapy. (Abstract #6611)
  Theodore Stewart Gourdin

• High frequency of BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as revealed by RT-PCR and interphase FISH: Association with disease biology and treatment outcome. (Abstract #6612)
  Zafar Iqbal
• Safety and efficacy of dose escalated liposomal amphotericin B in adult leukemia patients with refractory invasive fungal infections: A single institution report. (Abstract #6613)
  Sherry Mathew

• CDKN2A deletion to predict relapse in adult B-cell acute lymphoblastic leukemia (B-ALL). (Abstract #6614)
  Preet Paul Singh

• Time to ATRA in suspected newly diagnosed acute promyelocytic leukemia and association with early death rate at a non-cancer center institution: Are we meeting the target? (Abstract #6615)
  Gulam Abbas Manji

• Epigenetically induced expression of CD30 in T-PLL: A rationale for the use of brentuximab vedotin. (Abstract #6616)
  Zainul Hasanali

• A seasonal pattern of presentation in younger patients with de novo acute myeloid leukemia (AML). (Abstract #6617)
  Benjamin Jacob Drapkin

• The prognostic role of serum albumin in patients receiving induction chemotherapy for acute myeloid leukemia (AML). (Abstract #6618)
  Hossein Sadrzadeh

• Initial characterization of the toxicity and efficacy of elacytarabine (CP-4055), a novel antileukemic agent, using a multidimensional exposure-response relationship model. (Abstract #6619)
  Murray P Ducharme

• Azacitidine as induction therapy of elderly patients with acute myelogenous leukemia. (Abstract #6620)
  Cyrus Khan

• Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (Abstract #6621)
  Philip C. Amrein

• Use of granulocytes concentrates from a single high yield apheresis to support more than one patient. (Abstract #6622)
  Fleur M Aung

• Novel risk factors for osteonecrosis of the jaw in multiple myeloma: A RADAR report. (Abstract #6623)
  Jaimee S Holbrook

• Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. (Abstract #6624)
  Srdan Verstovsek
• Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT). (Abstract #6625^)

  Claire N Harrison

• Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. (Abstract #6626^)

  Jean-Jacques Kiladjian

• Post hoc analysis of association between treatment response and various indicators of efficacy and safety in a randomized phase III trial of decitabine in older patients with acute myeloid leukemia. (Abstract #6627)

  Mark D Minden

• Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes. (Abstract #6628)

  Xiaomei Ma

• History of autoimmunity to predict clinical response to DNA methyltransferase inhibitors (DNMTI) in myelodysplastic syndromes (MDS), and MDS-derived acute myeloid leukemias (AML). (Abstract #6629)

  Ashkan Emadi

• Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x10^9/L. (Abstract #6630)

  Moshe Talpaz

• Correlation of TCR diversity with immune reconstitution after cord blood transplant. (Abstract #6631)

  Ryan Emerson

• Post hoc analysis of relationship between baseline white blood cell count and renal and hepatic function and response in a randomized phase III trial of decitabine in patients age 65 or older with acute myeloid leukemia. (Abstract #6632)

  Jacques Delaunay

• Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y90(IT-Y90) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL). (Abstract #6633)

  Frederic Peyrade

• Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Design of CA180-363, a phase II, open-label randomized trial. (Abstract #TPS6634)

  Geralyn C. Trudel

• Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib. (Abstract #TPS6635)

  Michael Andreeff
Brd. 29C
• A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #TPS6636)
  
  Michael R. Savona

Brd. 30A
• VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia. (Abstract #TPS6637)
  
  Farhad Ravandi

Brd. 30B
• Prospective, observational registry of branded imatinib (IM) and nilotinib (NIL) exposure in pregnant women: Voluntary post-authorization safety study. (Abstract #TPS6638)
  
  Matthews Juma

Brd. 30C
• JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocytopenia (ET) MF with splenomegaly. (Abstract #TPS6639)
  
  Animesh Dev Pardanani

Brd. 31A
• An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocytopenia myelofibrosis (PET-MF). (Abstract #TPS6640)
  
  Philipp D. le Coutre

Brd. 31B
• A randomized phase II, open-label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocytopenia (ET) who are resistant or intolerant to hydroxyurea. (Abstract #TPS6641)
  
  Ayalew Tefferi

Brd. 31C
• A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocytopenia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to<100 x 10>9/l. (Abstract #TPS6642^)
  
  Heinz Gisslinger

Brd. 31D
• RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU). (Abstract #TPS6643^)
  
  Srdan Verstovsek

**Session Title:** Lymphoma and Plasma Cell Disorders  
**Session Type:** General Poster Session  
**Time:** 1:15 PM - 5:15 PM  
**Location:** S Hall A2

Brd. 32A
• Survival with splenectomy in splenic marginal zone lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. (Abstract #8044)
  
  Adam J. Olszewski
Brd. 32B
• Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. (Abstract #8045)
  Jorge J. Castillo

Brd. 32C
• Early determination of treatment sensitivity in HIV-related Hodgkin lymphoma by FDG-PET/CT after two cycles of ABVD chemotherapy: A European Cooperative Study Group on AIDS and Tumors (GECAT) study. (Abstract #8046)
  Nicolas Mounier

Brd. 32D
• The utility of serum lactate dehydrogenase (LDH) in the follow-up of patients with diffuse large B-cell lymphoma (DLBCL). (Abstract #8047)
  Navneeth Rao Bongu

Brd. 32E
• Association of low expression of VEGF121 soluble isoform with prognostic impact and survival in patients with activated B-cell-like (ABC-like) diffuse large B-cell lymphoma (DLBCL) from the CORAL trial. (Abstract #8048)
  Catherine Thieblemont

Brd. 32F
• Transformation of follicular lymphoma in the era of immuno-chemotherapy: A population-based study from British Columbia. (Abstract #8049)
  Abdulwahab J. Al-Tourah

Brd. 32G
• Long-term follow-up results of a phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma (NKTCL): JCOG0211. (Abstract #8050)
  Motoko Yamaguchi

Brd. 32H
• Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL). (Abstract #8051)
  Cliona Grant

Brd. 33A
• Radioimmunotherapy efficiency and safety in consolidation and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: An updated analysis of 230 patients of the international RIT-network. (Abstract #8052)
  Karin Hohloch

Brd. 33B
• LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL. (Abstract #8053)
  Craig B. Reeder

Brd. 33C
• Final results of phase I/II trial of vorinostat in combination with cyclophosphamide, etoposide, prednisone, and rituximab (R-CVEP) for elderly patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). (Abstract #8054)
  David J. Straus

Brd. 33D
• Association of prior rituximab exposure among patients undergoing autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma with inferior outcomes in males compared with females. (Abstract #8055)
  Aleksandr Lazaryan

  Timothy M Illidge

Brd. 33F
• Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed / refractory b-cell non-Hodgkin’s lymphoma (NCT00796731). (Abstract #8057)

  Bertrand Coiffier

Brd. 33G
• Hodgkin’s disease and HIV infection (HD-HIV): Prognostic factors in 596 patients (pts) within the group of European Cooperation on AIDS and Tumors (GECAT). (Abstract #8058)

  Michele Spina

Brd. 33H
• High affinity CD3 RECRUIT TandAb for T cell-mediated lysis of CD19+ tumor B cells. (Abstract #8059)

  Eugene Zhukovsky

Brd. 34A
• Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. (Abstract #8060)

  Lauren Shizue Maeda

Brd. 34B
• Determinants of and outcomes associated with chemoimmunotherapy dose density in elderly subjects with diffuse large B-cell lymphoma (DLBCL). (Abstract #8061)

  Usha S. Perepu

Brd. 34C
• Biweekly regimen of nonpegylated liposomal doxorubicin with cyclophosphamide, vincristine, and prednisone plus rituximab (R-COMP-14) as primary treatment for diffuse large B-cell lymphoma (DLBCL): Long-term follow-up of a phase II study. (Abstract #8062)

  Joaqui-n Herrero

Brd. 34D
• Progression-free survival for subsequent relapses in patients with peripheral T-cell lymphoma (PTCL). (Abstract #8063)

  Steven M. Horwitz

Brd. 34E
• MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study. (Abstract #8064)

  Peter Martin

Brd. 34F
• Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. (Abstract #8065)

  Trishna Goswami

Brd. 34G
• Dose- and time-intensified ABVD without radiotherapy (RT) for advanced-stage Hodgkin lymphoma (HL) with mediastinal bulky disease (MBD). (Abstract #8066)

  Gaetano Corazzelli
• Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP. (Abstract #8067)

  Nicolas Batty

• Prognostic value of etoposide area under the curve (AUC) in lymphoma patients treated with BEAM regimen and ASCT: Multicenter study of Groupe d’Etudes des Lymphomes de l’Adulte (GELA). (Abstract #8068)

  Olivia Bally

• Central nervous system involvement in T-cell lymphomas: A single center experience. (Abstract #8069)

  Ronit Gurion

• Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. (Abstract #8070)

  Ranjana Advani

• Ocular adnexal lymphoma (OAL)-outcomes for 82 patients (pts) treated at a single center. (Abstract #8071)

  Craig Anthony Portell

• The impact of race, age, and sex in follicular lymphoma (FL): A comprehensive SEER analysis in the pre- and post-rituximab (R) eras. (Abstract #8072)

  Chadi Nabhan

• Phase I trial of fenretinide (4-HPR) intravenous emulsion in hematologic malignancies: A California Cancer Consortium study (PhI-42). (Abstract #8073)

  Ann Mohrbacher

• Use of exon-based transcriptome profiling to identify novel signaling pathways and survival associated genes in diffuse large B-cell lymphoma. (Abstract #8074)

  Sirpa Leppa

• Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas. (Abstract #8075)

  Sonali M. Smith

• Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011. (Abstract #8076)

  Sean Whittaker

• Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease. (Abstract #8077)

  Andrea Gallamini

• Association of tumor-associated macrophages of M2 subtype with outcome in follicular lymphoma. (Abstract #8078)

  Clarinda Wei Ling Chua
• The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study. (Abstract #8080)

   Andrew M. Evens

Brd. 36F
• Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab. (Abstract #8081)

   Jennifer L. Wayne

Brd. 36G
• Disruption of the eIF4F translation initiation complex as a determinant of diffuse large B-cell lymphoma responsiveness to enzastaurin (LY317615.HCl) and its primary metabolite (LY326020). (Abstract #8082)

   Jeremy Richard Graff

Brd. 36H
• Use of the cumulative amount of serum-free light chains (sFLC) at diagnosis and PET2 for the early identification of high risk of treatment failure in Hodgkin lymphoma (cHL). (Abstract #8083)

   Rosaria De Filippi

Brd. 37A
• An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas. (Abstract #8084)

   Robert M. Crescentini

Brd. 37B
• Prevention of adverse events during treatment of HIV-associated Hodgkin lymphoma with ritonavir and zidovudine. (Abstract #8085)

   Sonia Sandhu

Brd. 37C
• Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma (Abstract #8086)

   Ajay K. Nooka

Brd. 37D
• Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len). (Abstract #8087)

   Balaji Balasa

Brd. 37E
• A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM). (Abstract #8088)

   Benjamin M. Cherry

Brd. 37F
• Costimulatory molecule profiles and NK cell recovery after autologous hematopoietic cell transplantation (HCT) in multiple myeloma (MM) patients. (Abstract #8089)

   Myo Htut

Brd. 37G
• Retrospective analysis of second malignancies in patients with multiple myeloma. (Abstract #8090)

   Giampaolo Talamo
• Predictive value of baseline serum MIP-1α and CRP on symptom burden and tumor response to induction therapy in patients with multiple myeloma. (Abstract #8091)
  
  Charles S. Cleeland

• Second autologous stem cell transplantation as a strategy for management of relapsed multiple myeloma. (Abstract #8092)
  
  Wilson I. Gonsalves

• Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma. (Abstract #8093)
  
  Krina K. Patel

• Predicting bortezomib-related severe neurologic adverse events by measuring proteasome activity in PBMCs. (Abstract #8094)
  
  Yukiko Cho

• Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. (Abstract #8095)
  
  Brian G. Durie

• Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. (Abstract #8096)
  
  Geetika Srivastava

• Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study. (Abstract #8097)
  
  Jae Hoon Lee

• A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen. (Abstract #8098)
  
  James R. Berenson

• Effect of matrix metallopeptidase 13 (MMP13) on multiple myeloma (MM) cells, osteoclast (OCL) activity, and bone resorption. (Abstract #8099)
  
  Jing Fu

• Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM). (Abstract #8100)
  
  Jonathan L. Kaufman

• Effect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival. (Abstract #8101)
  
  Charise Gleason
• Association of bone marrow plasma cell infiltration pre-auto transplant with adverse outcomes in multiple myeloma. (Abstract #8102)
  
  Qaiser Bashir

• Patterns of nonhematologic malignancies in a population of African American veterans with monoclonal gammapathy of unknown significance (MGUS). (Abstract #8103)
  
  Hady Ghanem

• Role of immune-related conditions in smoldering myeloma and MGUS. (Abstract #8104)
  
  Mary Kwok

• Does stage migration exist in active multiple myeloma (MM)? (Abstract #8105)
  
  Prashant Kapoor

• Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenström’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors. (Abstract #8106)
  
  Guang Yang

• Use of whole genome sequencing to identify highly recurrent somatic mutations in Waldenström’s macroglobulinemia. (Abstract #8107)
  
  Zachary R Hunter

• miRNA expression profiling of CD20+ plasma cell myeloma (PCM): Upregulation of miR-155 shedding new insight into disease biology and clinicopathologic behavior. (Abstract #8108)
  
  Ravindra Kolhe

• Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL). (Abstract #TPS8109)
  
  Daniel Oscar Persky

• Phase III study of investigational MLN8237 (alisertib) versus investigator’s choice in patients (pts) with relapsed/refractory (rel/ref) peripheral T-cell lymphoma (PTCL). (Abstract #TPS8110)
  
  Owen O’Connor

• Pilot study of MAGE-A3 protein vaccination and autologous stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM). (Abstract #TPS8111)
  
  Adam D. Cohen

• ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004). (Abstract #TPS8112)
  
  Sagar Lonial

• ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). (Abstract #TPS8113)
  
  Meletios A. Dimopoulos
• A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009). (Abstract #TPS8114)
  Andrzej J. Jakubowiak

• A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). (Abstract #TPS8115)
  Jesus G. Berdeja

• Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. (Abstract #TPS8116)
  John Anthony Lust

• Recruitment in a randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in patients with multicentric Castleman’s disease. (Abstract #TPS8117)
  Frits Van Rhee

• PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL). (Abstract #TPS8118)
  Tongyu Lin

---

**Session Title:** Tumor Biology

**Session Type:** General Poster Session

**Time:** 1:15 PM - 5:15 PM

**Location:** S Hall A2

• Homeobox B9: A potential surrogate marker for bevacizumab in combination with chemotherapy in colorectal cancer. (Abstract #10531)
  Yoshinori Hoshino

• VEGF pathway polymorphisms may be associated with overall survival in lapatinib-treated breast cancer patients – an exploratory study (Abstract #10532)
  Colin F. Spraggs

• Isolation of circulating tumor cells using a novel EMT-based capture method. (Abstract #10533)
  Rhonda Lynn Bitting

• Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. (Abstract #10534)
  Jorge Barbazan

• Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting. (Abstract #10535)
  Saswati Hazra
Brd. 42A
- In vivo isolation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients by a medical device. (Abstract #10536)
  
  Lukasz Gasiorowski

Brd. 42B
- A new medical device for in vivo capturing of circulating tumor cells in breast cancer (BC) patients. (Abstract #10537)
  
  Dawid Murawa

Brd. 42C
- Prognostic and diagnostic value of Ewing family of tumors (EFTs)-associated fusion transcripts detected in peripheral blood specimens. (Abstract #10538)
  
  Joanna Przybyl

Brd. 42D
- Circulating melanoma cells isolated from clinical blood samples and characterized by full-length mRNA sequencing at single-cell level. (Abstract #10539)
  
  Yu-Chieh Wang

Brd. 42E
- HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial. (Abstract #10540)
  
  Bernadette Anna Sophia Jaeger

Brd. 42F
- Detection and HER2 expression of circulating tumor cells in advanced gastric cancer patients. (Abstract #10541)
  
  Satoshi Matsusaka

Brd. 42G
- Serum hepatocyte growth factor and interleukin-6 as prognostic markers for stage III non-small cell lung cancer. (Abstract #10542)
  
  Hideki Ujiie

Brd. 42H
- Promoter methylation of MGMT in paired primary and recurrent glioblastomas. (Abstract #10543)
  
  Li Bie

Brd. 43A
- DJ-1 as a predictor of pathologic complete remission of neoadjuvant chemotherapy with breast cancer patients. (Abstract #10544)
  
  Takahiko Kawate

Brd. 43B
- Correlation between miRNA (miR) and gene expression profiles (GEP) and response to neoadjuvant chemotherapy (NT) in patients with locally advanced and inflammatory breast cancer (BC). (Abstract #10545)
  
  Sierra Mi Li

Brd. 43C
- Evaluation of CYP3A5, VEGF-a, and VEGFR2 polymorphisms as markers of sunitinib toxicity. (Abstract #10546)
  
  Cristina Rodriguez de Antona

Brd. 43D
- Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study. (Abstract #10547)
  
  Ana Custodio
• Different EGFR/KRAS mutation spectrums in lung cancer between never smokers and heavy smokers. (Abstract #10548)
  Kazuya Takamochi

• Combined targeting of LSD1 (KDM1A) and histone deacetylases exerts superior efficacy against human AML. (Abstract #10549)
  Warren Fiskus

• Prediction of late metastasis in node-negative breast cancer. (Abstract #10551)
  Marcus Schmidt

• Prognostic role of microRNA polymorphisms in advanced gastric cancer patients. (Abstract #10552)
  Linnea Stenholm

• Activation of and dependence on ataxia telangiectasia mutated kinase in PTEN-deficient tumor cells. (Abstract #10553)
  Nuala McCabe

• Central review of discordant samples for microarray based on ER, PR, and HER2 and local IHC/FISH assessment worldwide from 827 patients. (Abstract #10554)
  Jelle Wesseling

• Topoisomerase II alpha gene status, HER2, and microtubule-associated protein tau as predictors of pathologic complete response after neoadjuvant chemotherapy. (Abstract #10555)
  Agust Barnadas

• ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. (Abstract #10556)
  Kalai Khadija

• Exosomal-miRNA profiles as diagnostic biomarkers in cervical cancer. (Abstract #10557)
  Hirotaka Nishi

• Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer. (Abstract #10558)
  Natalie Galanina

• Use of next-generation sequencing (NGS) to detect high frequency of targetable alterations in primary and metastatic breast cancer (MBC). (Abstract #10559)
  Lajos Pusztai

• EGFR exon 20 insertion mutations: Incidence and clinicopathologic characteristics in U.S. patients with lung adenocarcinoma. (Abstract #10560)
  Maria E. Arcila
Brd. 45B
• Independent validation of prognostic value of 22 microRNAs (miRs) in stage I-II squamous cell lung cancer (SqCLC). (Abstract #10561)
  
  Marcin Tomasz Skrzypski

Brd. 45C
• Lymphopenia combined with low TCR diversity to predict overall survival in metastatic breast cancer patients. (Abstract #10562)
  
  Manuarii Manuel

Brd. 45D
• Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy. (Abstract #10563)
  
  Brent Allen Hanks

Brd. 45F
• Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients. (Abstract #10565)
  
  Maria Libera Ascierto

Brd. 45G
• Comparative analysis of myeloid-derived suppressor cell (MDSC) subsets in patients with gastrointestinal (GI) malignancies. (Abstract #10566)
  
  Austin G. Duffy

Brd. 45H
• Correlation of the maximum standardized uptake value for f-18 fluorodeoxyglucose with molecular subtype and survival in advanced breast cancer. (Abstract #10567)
  
  Zhen Jia

Brd. 46A
• Extracellular matrix and breast cancer cells' response to trastuzumab: The role of glycosaminoglycans, heparanases, and syndecan-1. (Abstract #10568)
  
  Maria Aparecida Silva Pinhal

Brd. 46B
• Detection of EML4-ALK in serum RNA from lung cancer patients using MassARRAY platform. (Abstract #10569)
  
  Keita Kudo

Brd. 46C
• Hybrid PET-MRI of the breast: A promising tool for the characterization of breast tumors. (Abstract #10570)
  
  Katja Pinker-Domenig

Brd. 46D
• Online biomarker validation of survival-associated biomarkers in breast and ovarian cancer using microarray data of 3,862 patients. (Abstract #10571)
  
  Balazs Gyorffy

Brd. 46E
• The effect on detection rate of second cancers after the addition of MRI to conventional screening mammography in patients with a history of breast cancer. (Abstract #10572)
  
  Chana Weinstock

Brd. 46F
• FDG-PET and CT as early predictors of outcome in NSCLC patients treated with erlotinib. (Abstract #10573)
  
  Robert Iannone
Br. 46G
• Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy. (Abstract #10574)

  Jonathan Riess

Br. 46H
• Accuracy of microRNA-based classification of metastases of unknown primary. (Abstract #10575)

  Nicholas Pavlidis

Br. 47A
• A gene expression profile test that distinguishes ovarian from endometrial cancers. (Abstract #10576)

  Anita Lal

Br. 47C
• Preoperative detection of circulating tumor cells in patients with colorectal carcinoma: Correlation with clinicopathologic variables and recurrence. (Abstract #10578)

  Hideyasu Sakihama

Br. 47D
• Use of early 18f-fluorodeoxyglucose-positron emission tomography to predict clinical outcome of patients with advanced non-small cell lung cancer on gefitinib treatment versus carboplatin plus paclitaxel. (Abstract #10577)

  Masaki Kanazu

Br. 47E
• Defining a FISH chromosomal aneusomy panel for predicting lung cancer in the setting of CT-detected lung nodules. (Abstract #10580)

  Wilbur A. Franklin

Br. 47G
• Antigens diagnoses in paraneoplastic neurological syndromes. (Abstract #10582)

  Halina Rudnicka

Br. 47H
• Antagonistic activity of acolbifene, fulvestrant, tamoxifen, and raloxifene on cancer-associated genes in the mouse mammary gland. (Abstract #10583)

  Ezequiel Calvo

Br. 48A
• Estimation of expected survival time using gene expression profiling for tumor site origin. (Abstract #10584)

  William David Henner

Br. 48B
• Novel malignant-mesothelioma-associated antigens (Gene-X and THBS-2) in the diagnosis of malignant pleural mesothelioma (MPM). (Abstract #10585)

  Fumihiro Tanaka
• Multiplex TaqMan assays for a 7-gene prognostic immune response score to differentiate risk among women with ER-negative breast cancer. (Abstract #10586)
  
  
  John J. Sninsky

• Specific and sensitive detection of BRAF and KRAS mutations in clinical samples. (Abstract # 10587)
  
  Vanessa Kelchner

• Multisite validation of a 92-gene molecular classifier: Diagnostic accuracy and clinical utility in metastatic cancer. (Abstract #10588)
  
  Catherine A. Schnabel

• A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer. (Abstract #10589)
  
  Joseph W. Kim

• Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients. (Abstract #10590)
  
  Gary A. Palmer

• Combining semiconductor-based sequencing with amplicon-based cancer gene panels: A rapid next-gen approach to clinical cancer genotyping. (Abstract #10591)
  
  Christopher L. Corless

• Genomic profiling of non-small cell lung cancer (NSCLC) for personalized targeted therapy using CT-guided transthoracic needle biopsy (TTNB). (Abstract #10592)
  
  Ritu R. Gill

• Prevalence of TP53 p.R337H mutation in children with cancer from a public hospital in southern of Brazil. (Abstract #10593)
  
  Juliana Giacomazzi

• Prognostic value of “angiogenic” risk score in early-stage NSCLC. (Abstract #10594)
  
  Elena Sanmartin

• Activation of angiogenic pathway in the prediction of pathologic response to bevacizumab-based neoadjuvant therapy in breast cancer. (Abstract #10595)
  
  Jose Manuel Lopez-Vega

• Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay. (Abstract #10596)
  
  Susana Benlloch

• Response and long-term outcomes after neoadjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping by MammaPrint and BluePrint. (Abstract #10597)
  
  Stefan Gluck
• The efficacy of targeted next-generation sequencing for detection of clinically actionable mutations in cancer. (Abstract #10598)
  Yu-Ye Wen

• Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer. (Abstract #10599)
  Volkmar Mueller

• A circulating epithelial cell type merging stem cell, EMT, and hypoxic stress markers in early and advanced breast cancer. (Abstract #10600)
  Leo Habets

• Exploratory study of histopathological and biomolecular characteristics of breast cancer in two different populations: African (Tanzania) and Caucasian (Italy). (Abstract #10601)
  Patrizia Serra

• The components of progression as explanatory variables for overall survival in the RECIST database. (Abstract #10602)
  Saskia Litière

• pAKT expression in paraffin-embedded xenograft tumors after fixation delays and human breast cancer by optimized immunohistochemistry. (Abstract #10603)
  Sherry X. Yang

• Monitoring of plasma pro-GRP level during EGFR-TKI treatment. (Abstract #10604)
  Yuko Kawano

• Anti-AML activity of a novel beta-catenin antagonist BC2059. (Abstract #10605)
  Kapil N. Bhalla

• Evaluation of the clinical utility of kallikrein-related peptidase 6 gene (KLK6) downregulation in breast cancer. (Abstract #10606)
  Kleita Michaelidou

• p53 mutations in advanced cancers: Clinical characteristics and outcomes in a phase I setting. (Abstract #10607)
  Rabih Said

• Study of the usefulness of angiotensin type 1 receptor (AGTR1) as a possible response predictor in patients with metastatic breast cancer (mBC) subjected to chemotherapy and treatment with bevacizumab (AVALUZ Study). (Abstract #10608)
  Juan De la Haba- Rodriguez

• The lipid metabolome of clear cell renal cell carcinoma (CCRCC). (Abstract #10609)
  Saby George
Brd. 51C
• Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation. (Abstract #10610)
  Kosuke Tanaka
Brd. 51D
• Evaluation of EZH2 SNPs in cholangiocarcinoma patients. (Abstract #10611)
  Elisa Paolicchi
Brd. 51E
• Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations. (Abstract #10612)
  Emrullah Yilmaz
Brd. 51F
• Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer. (Abstract #10613)
  Windy Marie Dean-Colomb
Brd. 51G
• Isolation and expansion of circulating tumor cells (CTC) from melanoma patients using a novel cell culture technique. (Abstract #10614)
  John R. McGregor
Brd. 51H
• Zoledronic acid effect on circulating RANK/RANK-l/OPG axis in cancer patients. (Abstract #10615)
  Toni Ibrahim
Brd. 52A
• Role of proliferation in response to neoadjuvant chemotherapy in GEICAM/2006-03 and GEICAM/2006-14 breast cancer patients. (Abstract #10616)
  E. Alba
Brd. 52B
• Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomized in a chemotherapy phase III trial. (Abstract #10617)
  Adam Vilmar
Brd. 52C
• Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i). (Abstract #10618)
  Komal L. Jhaveri
Brd. 52D
• Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2. (Abstract #10619)
  David Neal Franz
Brd. 52E
• Serum activinA and TGF-β as biomarkers of breast cancer bone metastasis behavior. (Abstract #10620)
  Christina L. Addison
Brd. 52F
• Identification and validation of plasma protein biomarker panels for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry. (Abstract #10621)
  Hyeong-Gon Moon
• Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia patients. (Abstract #10622)
  
  Georg A. Bjarnason

• New mechanistic insights into possible radiobiologic and pathophysiologic explanations for unexpectedly impressive outcomes data observed for hormone-refractory metastatic prostate cancer patients treated with radium 223. (Abstract #10623)
  
  Roger M. Macklis

• Synthetic lethality of EGFR blockade in the context of tumor hypoxia. (Abstract #10624)
  
  Haruhiko Makino

• Using CHFR expression to predict response and survival after first line treatment with carboplatin-paclitaxel in NSCLC. (Abstract #10625)
  
  Rathi Narayana Pillai

• DNA damage responses in relation to late effects following radiotherapy for early breast cancer. (Abstract #10626)
  
  Melvin Chua

• Correlation between in vitro chemotherapy sensitivity and PARP-1 expression in patients with breast cancer. (Abstract #10627)
  
  Cornelia Liedtke

• In silico identification of an epithelial core signature in human tumors. (Abstract #10628)
  
  Chirayu Pankaj Goswami

• Intestinal HIF-2 to protect against radiation-induced gastrointestinal syndrome. (Abstract # 10629)
  
  Cullen M Taniguchi

• Molecular profiling of uveal melanoma patients. (Abstract #10630)
  
  Zoran Gatalica

• Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early-stage breast cancer using a microfluidic-based cell enrichment and extraction platform (OncoCEE). (Abstract #TPS10631)
  
  Savitri Krishnamurthy

• The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint. (Abstract #TPS10632)
  
  Ramon Salazar

• Emerging findings in the Cancer Research UK stratified medicine program. (Abstract #TPS10633^)
  
  Emily Shaw
Highly sensitive determination of PIK3CA exon 9 and 20 hotspot mutations in breast tumors. (Abstract #TPS10634)
Alexandre Harle

ACRIN 6684 assessment of tumor hypoxia in glioblastoma using 18F-fluoromisonidazole with PET and MRI. (Abstract #TPS10635)
Elizabeth Robins Gerstner

---

**Session Title:** ASCO/American Society of Hematology (ASH) Joint Session

**Session Type:** Special Session

**Time:** 3:00 PM - 4:15 PM

**Location:** E354b

- Opening Remarks
  Michael Paul Link, MD (Co-Chair)

- Discussion for ASH Abstract #: 40379
  Ross L. Levine, MD

- Clonal Evolution of Pre-leukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia (ASH Abstract #: 40379)
  Ravindra Majeti, MD

- Discussion for ASH Abstract #: 39189
  Armand Keating, MD (Co-Chair)

  - Increased Incidence of Chronic Graft-versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial (ASH Abstract #: 39189)
    Claudio Anasetti, MD

- Discussion for ASH Abstract #: 36489
  Margaret Ragni, MD

  - Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B (ASH Abstract #: 36489)
    Andrew Davidoff, MD

- Discussion for ASH Abstract #: LBA-6
  John Leonard, MD

  - Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. (ASH Abstract #: LBA-6)
    Brad S. Kahl, MD

---

**Session Title:** Castration-Resistant Prostate Cancer: New Insights into Biology and Treatment (eQ&A)

**Session Type:** Education Session

**Time:** 3:00 PM - 4:15 PM

**Location:** E Hall D1

- Biologic Basis of Emerging Therapies in Prostate Cancer
  Robert Evan Reiter, MD

- Prognostic and Predictive Factors for Individualizing Treatment for Castration-Resistant Prostate Cancer
  Andrew J. Armstrong, MD, ScM

- State-of-the-Art Management for the Patient with Castration-Resistant Prostate Cancer
  A. Oliver Sartor, MD (Chair)
Session Title: Doing It Right, and for Less: Implementing Practice Changes to Manage the Growing Complexities, Inefficiencies, and Costs of Cancer Care
Session Type: Education Session
Time: 3:00 PM - 4:15 PM
Location: S404
• Implementation of Clinical Practice Guidelines and Critical Pathways to Improve the Quality, Safety, Efficiency, and Cost of Cancer Care
  Adam Brufsky, MD, PhD (Chair)
• Using Simple Tools and Behavioral Changes to Improve Quality and Safety
  Bruce E. Hillner, MD
• Applying the Toyota Production System (or LEAN Process) to Health Care: Improving Quality, Safety and Efficiency to Deliver Better, Faster, and More Affordable Care
  Henry Orlando Otero, MD

Session Title: Gene Patenting: Effects on Biotechnology and Oncology
Session Type: Education Session
Time: 3:00 PM - 4:15 PM
Location: S100bc
• Current Status of Court Decisions on Gene Patents and Impact of Diagnostic Testing
  Roger David Klein, MD, JD
• Impact of Gene Patents on the Biotechnology Industry, with a Focus on Oncologic Pharmaceutical Development
  Hans Sauer, PhD, JD
• Gene Patents: History and Relevance to Oncologists
  Kenneth Offit, MD, MPH (Chair)

Session Title: Liver-Directed Therapeutic Options for Hepatocellular Carcinoma: Patient Selection and Clinical Outcomes
Session Type: Education Session
Time: 3:00 PM - 4:15 PM
Location: N Hall B1
• Patient Selection, Resection Type, and Clinical Outcomes of Hepatic Resection for Hepatocellular Carcinoma
  Kenneth Tanabe, MD
• Role of Radiation for Hepatocellular Carcinoma: Techniques and Outcomes
  Laura A. Dawson, MD (Chair)
• Interventional Radiologic Techniques for Hepatocellular Carcinoma: Emerging Data and Patient/Tumor Selection
  Fred T. Lee, MD

Session Title: Optimizing Efficient and Effective Care of Cancer Survivors
Session Type: Education Session
Time: 3:00 PM - 4:15 PM
Location: S100a
• Models of Care amongst Cancer Survivors
  Eva Grunfeld, MD, DPhil (Chair)
• Imaging of Cancer Survivors: How Much Is Too Much?
  Craig Earle, MD
• Coordination of Care among Cancer Survivors
  Paul Han, MD, MA, MPH

Session Title: Transition and Decision Making for Palliative Care of Patients with Pediatric Cancer
Session Type: Education Session
Time: 3:00 PM - 4:15 PM
Location: S504
- Communication and Transition to Palliative Care for the Patient with Pediatric Cancer  
  Jennifer W. Mack, MD (Chair)
- The Role of Hope In End-of-Life Decision Making  
  Chris Feudtner, MD, PhD, MPH
- Therapeutic Decision Making at the End of Life in Patients with Pediatric Cancer  
  Pamela S. Hinds, PhD, RN

**Session Title:** Treatment of Older Patients with Advanced Cancer: Balancing Efficacy with Toxicity (eQ&A)
**Session Type:** Education Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** E353
- Considerations in Dosing of Cancer Treatment for Older Patients  
  Heidi D. Klepin, MD, MS
- Multidisciplinary Approach for Decision Making and Treatment of Patients with Advanced Cancer  
  Supriya Gupta Mohile, MD, MS (Chair)
- Supportive Care Interventions to Maximize Treatment Efficacy  
  Arati Rao, MD

**Session Title:** Assessing Patients' Psychosocial Well-Being in Clinical Practice: Practical Considerations - Ticketed Session
**Session Type:** Meet the Professor Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** E451a
- Practical Considerations in Implementation of Psychosocial Screening in Clinical Practice  
  Paul B. Jacobsen, PhD

**Session Title:** Developing Patient-Centered Quality Metrics in Oncology Care: Where We Are and Where We're Going - Ticketed Session
**Session Type:** Meet the Professor Session  
**Time:** 3:00 PM - 4:15 PM  
**Location:** E451b
- Quality Improvement  
  Christopher S. Lathan, MD, MS, MPH

**Session Title:** Mutated Melanoma: The Role for MEK Inhibitors
**Session Type:** Clinical Science Symposium  
**Time:** 3:00 PM - 4:30 PM  
**Location:** E354a
- Co-Chair  
  Helen Gogas, MD
- Co-Chair  
  Jeffrey Alan Sosman, MD
- Discussion  
  David B. Solit, MD
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/Kmutant advanced or metastatic melanoma (MM). (Abstract #LBA8509)  
  Caroline Robert
• Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. (Abstract #8510)
  Jeffrey S. Weber

• Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. (Abstract #8511)
  Paolo Antonio Ascierto

• Discussion
  Patricia LoRusso, DO

Session Title: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Session Type: Oral Abstract Session

Time: 3:00 PM - 6:00 PM
Location: E Arie Crown Theater

• Chair
  John Timmerman, MD

• Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. (Abstract #2500)
  Robert Charles Newton

• A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies. (Abstract #2501)
  Hatem Hussein Soliman

• Isolation of human anti-MICA antibody from cancer patients responding to immunotherapies. (Abstract #2502)
  Kenneth F. May

• Discussion
  Thomas Gajewski, MD, PhD

• Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR). (Abstract #2503)
  Robert J. Kreitman

• A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. (Abstract #2504)
  Walter M. Fiedler

• Anti-CD3 immunotoxin to induce remissions in cutaneous T-cell lymphoma patients. (Abstract #2505)
  Arthur E. Frankel

• Discussion
  Louis M. Weiner, MD

• WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. (Abstract #2506)
  Zwi N. Berneman

• Phase IB study on combined intradermal (ID) and intravenous (IV) administration of autologous mRNA electroporated dendritic cells (DC) as a single-agent cellular immunotherapy or combined with ipilimumab. (Abstract #2507)
  Bart Neyns

• From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines. (Abstract #2508)
  Timothy J Vreeland

• Discussion
  John Timmerman, MD

Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: Oral Abstract Session  
Time: 3:00 PM - 6:00 PM  
Location: E Hall D2

- Co-Chair  
  Ronan Joseph Kelly, MD, MBA
- Co-Chair  
  Raffit Hassan, MD

- LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. (Abstract #LBA7500)  
  James Chih-Hsin Yang
- TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. (Abstract #LBA7501)  
  Marina Chiara Garassino
- SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy. (Abstract #7502)  
  Edward S. Kim
- Discussion  
  Benjamin J. Solomon, MBBS, PhD
- Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). (Abstract #7503)  
  Pasi A. Janne
- Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. (Abstract #7504)  
  Robert Charles Doebele
- Multiplex testing for driver mutations in squamous cell carcinomas of the lung. (Abstract #7505)  
  Paul K. Paik
- Discussion  
  Joel W. Neal, MD, PhD
- A randomized phase III trial of single agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. (Abstract #7506)  
  Rogerio Lilenbaum
- PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (Abstract #LBA7507)  
  Luis Paz-Ares
- Discussion  
  Gregory Peter Kalemkerian, MD

Session Title: Sarcoma  
Session Type: Oral Abstract Session  
Time: 3:00 PM - 6:00 PM  
Location: S406

- Co-Chair  
  William D. Tap, MD
• Co-Chair  
  Rashmi Chugh, MD
• Predicting survival in primary resected retroperitoneal soft tissue sarcoma: A specific nomogram built on three major sarcoma center data sets. (Abstract #10000)  
  Alessandro Gronchi
• How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas. (Abstract #10001)  
  Robert G. Maki
• Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma. (Abstract # 10002)  
  Mark Andrew Dickson
• Discussion  
  Robin Lewis Jones, MD
• A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS). (Abstract #10003)  
  Gary K. Schwartz
• A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma. (Abstract #10004)  
  Mrinal M. Gounder
• GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group (FSG)/French and U.S. National Cancer Institutes phase II collaborative study. (Abstract #10005)  
  Antoine Italiano
• Discussion  
  Lee J. Helman, MD
• An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. (Abstract # 10006)  
  Isabelle Ray-Coquard
• Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial. (Abstract #10007)  
  Antoine Adenis
• Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. (Abstract #LBA10008)  
  George D. Demetri
• Discussion  
  Grant A. McArthur, MBBS, PhD

Session Title: ASCO/Children's Oncology Group (COG) Joint Session: The Risks-Benefits of Cardioprotection in Children with Cancer

Session Type: Special Session

Time: 4:45 PM - 6:00 PM

Location: S504

• Co-Chair  
  Michael Paul Link, MD (Co-Chair)
• Co-Chair  
  Peter C. Adamson, MD (Co-Chair)
• United States Clinical Perspective  
  Stephen E. Sallan, MD
Education Session
E353
Location: E353
Session Title: Angiogenic Targeting after 10 Years of Clinical Trials and Practice (eQ&A)
Session Type: Education Session
Time: 4:45 PM - 6:00 PM
Where Did We Go Right and Where Did We Go Wrong: A Historical Perspective
Lee S. Rosen, MD
Mechanisms of Resistance to Antiangiogenic Agents
Lee M. Ellis, MD
Putting Angiogenic Biomarkers to Good Use
Michael L. Maitland, MD, PhD (Chair)

Session Title: Constructing a Top Five List for Oncology: The ASCO Top Five List
Session Type: Education Session
Time: 4:45 PM - 6:00 PM
Welcome and Introduction
Lowell E. Schnipper, MD (Chair)
Cancer-directed Treatments in Patients for Whom Such Interventions are Likely to be Futile
Thomas J. Smith, MD
Staging of Early Breast Cancer at Low Risk for Metastasis
Douglas W. Blayney, MD
Staging of Early Prostate Cancer at Low Risk for Metastasis
Derek Raghavan, MD, PhD
Surveillance of Individuals Treated for Breast Cancer with Curative Intent
Patricia A. Ganz, MD
White Cell Stimulating Factors for Primary Prevention of Febrile Neutropenia
Therese M. Mulvey, MD

Session Title: Genomic Cancer Risk Assessment: A Translational Challenge
Session Type: Education Session
Time: 4:45 PM - 6:00 PM
Location: S100bc
Individualized Genomic Risk Assessment for Colorectal Cancer
Stephen B. Gruber, MD, PhD, MPH
Application of Next-Generation Sequencing to Familial Breast Cancer
Fergus J Couch, PhD
Clinical Applications of Genomic Risk Information
Zsofia Kinga Stadler, MD (Chair)

Session Title: Patient Portals in Oncology
Session Type: Education Session
Time: 4:45 PM - 6:00 PM
Location: S404
Use of a Patient Portal in an Oncology Practice
Elizabeth Schmidt Rodriguez, RN (Chair)
Experience of Patient Portal with Real-Time Release of Laboratory Results
Henry Feldman, MD
**Session Title:** Lessons Learned in Drug Development for Children with Cancer - Ticketed Session

**Session Type:** Meet the Professor Session

**Time:** 4:45 PM - 6:00 PM

**Location:** E451a

- Lessons Learned in Drug Development for Children with Cancer

  *Gregory H. Reaman, MD*